Photodynamic activity of a glucoconjugated Silicon(IV) phthalocyanine on human colon adenocarcinoma. by Chan, Man Hung. & Chinese University of Hong Kong Graduate School. Division of Life Sciences.
Photodynamic Activity of a Glucoconjugated 
Silicon(IV) Phthalocyanine on Human 
Colon Adenocarcinoma 
CHAN�Man Hung 
A Thesis Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Master of Philosophy 
In 
Biochemistry (Science) 
The Chinese University of Hong Kong 
July 2009 
P 1 5 FEB 1 1 1 
V. ‘ ！ sp l 
liBRi.Ry SYSTEf^^ 
Examination Committee List 
Professor Siu-Kai Kong (Chair) 
Professor Wing-Ping Fong (Thesis Supervisor) 
Professor Kwok-Nam Leung (Committee Member) 
Professor Nai-Ki Mak (External Examiner) 
ii 
I declare that the assignment here submitted is original except for source material explicitly 
acknowledged, and that the same or related material has not been previously submitted for 
another course. I also acknowledge that I am aware of University policy and regulations on 
honesty in academic work, and of the disciplinary guidelines and procedures applicable to 
breaches of such policy and regulations, as contained in the website. 
30th juiv 2007 
Sign 命 e Date 
Chan Man Hung 07019230 
Name Student ID 
BCH 806R Thesis Research 




I would like to express my sincere gratitude to my supervisor Prof. Wing-Ping Fong 
for providing me with this precious opportunity to study the M.Phil degree in CUHK. The 
experience of doing research here is invaluable for my life. I also want to give thanks for his 
patient guidance throughout my study. Finally I would like to thank my supervisor again who 
has reviewed and provided invaluable suggestions for the improvement of this thesis. 
I would like to thank Prof. Dennis Kei-Pui Ng and Prof. Pui-Chi Lo, Department of 
Chemistry, The Chinese University of Hong Kong. They have kindly provided me the 
chemical SiPcGlu for this study and given me support and help in the field of chemistry. 
I particularly want to express my thanks to Ms. Judy Wong, Mr. Chun-Pong Wong, 
Ms. Esther Yeung and Ms. Anna Cheang for their always spiritual and technical support 
throughout my study. Special thanks should also be given to Mr. Stanley Leung, Ms. Elaine 
Chan, Ms. Michel Chan and Mr. Cheung-Wai So. They all helped me a lot when I first 
entered this laboratory. 
iv 
Acknowledgements 
I also want to give special gratitude to my family who always support me throughout 
my study. I would also like to take this opportunity to give my thanks to my husband Daniel 
who I am deeply in love and treasure with. He has given me the most support throughout 
these two years, both spiritually and technically. 
Lastly, I must give thanks to my Lord who has led me here, given me the chance to 
learn, to grow and provided me everything I need. 
V 

























Photodynamic therapy (PDT) has emerged as a promising therapeutic modality for 
cancer, wet age-related macular degeneration and infectious disease. PDT involves the use of 
a non-toxic photosensitizer which, in the presence of light, is activated to produce the killing 
effect. We have synthesized a number of novel second or third generation photosensitizers, 
among them the glucoconjugated silicon(IV) phthalocyanine SiPcGlu is a promising 
candidate. In the in vitro studies, it is highly photocytotoxic against HT29 human colon 
adenocarcinoma. We have successfully demonstrated that reactive oxygen species (ROS) 
initiated cell death via Type I and Type II photoreactions. 
Photoactivation of SiPcGlu induced apoptosis in HT29 as measured by several 
parameters, including TUNEL, annexin V & propidium iodide staining and DNA laddering 
assays. Subcellular localization studies revealed that SiPcGlu exhibited a partial localization 
in mitochondria and endoplasmic reticulum. After PDT, immediate mitochondrial membrane 
depolarization and ROS production were resulted, followed by release of cytochrome c, 
activation of caspase-3 and PARP cleavage. Expression of the ER-stress chaperone protein 
GRP78 was induced and the level of cytosolic Ca^^ was elevated. The above findings showed 
that mitochondria and ER are the primary sites of photodamage. 
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Abstract 
The efficacy of SiPcGlu-PDT and the drug's biodistribution in HT29 tumor-bearing 
nude mice were also evaluated. Though the glucose moiety failed to target SiPcGlu towards 
tumor tissue, photoactivation of SiPcGlu by spotting medical laser onto the tumor can 
significantly inhibit tumor growth. Analysis of intrinsic toxicity also revealed that SiPcGlu 
with or without irradiation did not cause any apparent hepatic and cardiac injuries to the nude 
mice, indicating that SiPcGlu is a safe candidate for clinical PDT. 
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Chapter 1 Introduction . 
1.1 Background of photodynamic therapy (PDT) 
1.1.1 History of PDT 
Treatments using light and light-activated compounds were reported in ancient times 
and were used to treat a variety of disorders and malaise. The therapeutic use of light was 
first reported by Niels R. Finsen in the late nineteenth century. He discovered that light 
treatment could control skin manifestations of tuberculosis and the 1903 Nobel Prize was 
awarded to him for his work on phototherapy (Bonnett, 1995). Throughout the century, 
a few attempts were made to treat tumor tissue with photosensitizing agents, mainly with 
non-porphyrin photosensitizers. The first clinical application of PDT was described by 
Hermann von Tappeiner and Albert Jesionek who applied eosin topically to basal cell 
carcinomas prior to illumination (MacDonald and Dougherty, 2001). They later defined 
PDT as a dynamic interaction among light, photosensitizing agent and oxygen resulting in 
tissue destruction. In the 1960s, Richard Lipson and Samuel Schwartz isolated a tumor 
localizing impurity hematoporphyrin derivative (HpD), and used it as a tumor detecting 
agent and later recognized it as a photosensitizer to destroy tumor tissue (Lipson et al., 
1961). In the 1970s，Thomas J. Dougherty discovered that when placing radiation 
sensitizing agents in cell culture near laboratory windows, significant cell death was 
observed. He isolated and found that HpD in combination with red light could completely 
eradicate mouse mammary tumor growth (Allison et al., 2004). He injected a mixture of 
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porphyrins into the bloodstream of the mice with mammary tumors. After waiting a few 
days, the porphyrins accumulated in tumors and he shone red light on them. At that time, 
the experimental setup was primitive, using simply an old slide projector through a 35 mm 
red-colored slide to pass the light. In almost every case, the tumors turned out to be 
blackened and died after light treatment (Dougherty et al., 1975). The active fractions of 
HpD was later isolated and identified as a purified version named Photofrin®. Clinical 
studies were done in the following years with Photofrin® to treat patients with bladder and 
skin cancers. After these successful clinical studies, the approval of PDT, using Photofrin®, 
Axcan Pharma Inc., Mont-Saint-Hilaire, Canada was granted in 1993 and later in Japan, 
USA and parts of Europe for the treatment of esophageal, bladder, head and neck, skin and 
some stages of lung cancers (Lane, 2003). 
1.1.2 Photochemistry 
Upon absorption of light, the photosensitizer in the ground state is promoted to the 
short-lived excited singlet state and then converted to the more stable triplet state through 
electron spin conversion. The triplet state is long-lived enough to elicit chemical reactions 
and most part of the photodynamic actions take place at this stage. There are two types of 
photodynamic reactions (Figure 1.1). In the Type I photoreaction, the triplet photosensitizer 
can react directly with substrate, such as the cell membrane, and transfer a hydrogen atom 
3 
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or electron to form radicals. The radicals can interact with oxygen to produce oxygenated 
products (IO2) such as superoxide anions(02"), hydroperoxyls (HO2), hydrogen radicals 
( OH) and hydrogen peroxide (H2O2). These are reactive intermediates harmful to cells. 
Thereby the photosensitizer returns to the ground state. Alternately, the triplet 
photosensitizers can undergo Type II photoreaction in which they undergo an electron spin 
exchange with ground-state triplet oxygen (^02) to produce a cytotoxic singlet oxygen ('O2), 
a highly reactive oxygen species (ROS) which is the most damaging species generated 
during PDT (Calzavara-Pinton et al.，2007; Dolmans et al.，2003; Triesscheijn et al., 2006). 
The effects of almost all PDT drugs are oxygen-dependent. ROS are known to initiate a 
number of reactions with biomolecules, including amino acid residues (e.g. tryptophan) in 
proteins; unsaturated lipids, cholesterol and nucleic acid bases, particularly guanosine and 
guanine derivatives with the latter base more susceptible to ROS (Josefsen and Boyle, 
2008a). 
[ j j pe I r e a c t ^ , Type II reaction^ 
E g - E g � -
I oxygenated products i j 
Products of Products of 
oxidation oxidation 
Figure LI Mechanisms of action of PDT (Dolmans et al” 2003) 
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1.1.3 Principal stages of PDT 
PDT is a treatment requiring injection of photo sensitizer (in syringe or tube) (Stage 
I). The injection of drug can be done locally by subcutaneous injection or systemically by 
intravenous injection. The drug then accumulates in tumors (Stage II). After a certain time 
interval, the drug is activated by external illumination (Stage III), which is very often done 
on an outpatient basis. This induces cell death and tumor destruction (Stage IV) (Figure 1.2) 
(Chatterjee et aL, 2008). 
T 
4 _ 
^ ^ local 
^ ^ 一 一 一- - Stages of PDT 
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；卞 * • 、 产- • ' • ： * • • 
f. ^ ^ Application 
。一 ^ ^ M M S i S " / 
systemic 
Figure 1.2 Principle stages of PDT (Chatterjee et al” 2008) 
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1.1.4 Light sources of PDT 
The efficacy of light sources for PDT is determined by two factors. The first one is 
the absorption spectrum of the photosensitizer. A light source with an emission spectrum 
that corresponds to the absorption spectrum of the photosensitizer gives the higher efficacy. 
The second factor is the wavelength and penetration power of the light. Light with longer 
wavelength can penetrate into skin more deeply (Figure 1.3). Therefore, light in the far-red 
region is usually adopted for PDT as red light with wavelength > 650 nm can penetrate 
deeply into the skin down to the subcutaneous layers. 
Wavelength in nm 
• • 醫 冒 醒 • 醫 
；10% T W W • • W 0.5 _ 
20% f • B • y 1.0 _ 
33% 1 • • 34% 
• 冒 冒 3.0 mm 
55% I I 
82% 84% … — - o.O mm 
Figure 1.3 Depth ofpenetration of light with different wavelengths (Adapted from 
httD://www.bundp.net/?q=en/node/219) 
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There are three major groups of light source: broadband lamps, diode lamps and 
lasers. The traditionally used light sources in PDT are broad-spectrum lamps. Non-coherent 
broad-spectrum light sources in red and blue wavelengths, together with porphyrins, was the 
earliest and most frequently used light sources in PDT for cutaneous diseases. Nowadays, 
metal halogen lamps are frequently used as they are cheap and have high power intensity, 
therefore a reasonable light exposure time can be achieved. Moreover, they can be equipped 
with optical filter to cut off the shorter wavelengths which cannot be absorbed into skin. 
Diode lamps are small solid-state semiconductors with a high and reliable emission in a 
narrow bandwidth of 20-50 nm. They are simple to use and do not have any special 
electronic requirements. Another choice is laser which can elicit wavelengths matching the 
absorption peak of the photosensitizers (Calzavara-Pinton et al., 2007). They are highly 
efficient and so treatment time can be shortened. Lasers are the most frequently used light 
source as it can produce monochromatic light which is highly homogenous. Light delivery 
can be achieved by fiber-optics cable equipped with lenses and diffusers to allow optimal 
illumination of the tissues to be treated and minimize the illumination of healthy tissues 
(MacDonald and Dougherty, 2001). 
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1.2 Anti-tumor effect of PDT 
1.2.1 Mode of ceil death after PDT 
The crucial factors determining the types of cell death are cell type, subcellular 
localization and light dose (Castano et al.，2006). The subcellular localization of the 
photosensitizers determines the primary site of photodamage which triggers different types of 
cell death. Moreover, singlet oxygen can diffuse only 20 nm during its lifetime (half life: < 
0.04 |is). It can only damage biomolecules in its close proximity (Castano et al., 2004). 
Cellular structures having high photosensitizer and oxygen concentrations will preferentially 
be damaged. Therefore, the subcellular localization of photosensitizers triggers different 
pathways to cell death. In general, the photosensitizers with preferred localization in 
mitochondria (e.g. porphyrin-related compounds) wil l activate the apoptotic pathways within 
a certain threshold of oxidative stress (Agostinis et al., 2004). For photosensitizers localized 
in the plasma membrane, the photosensitization process can rapidly switch towards necrosis 
due to the loss of plasma membrane integrity and rapid depletion of intracellular ATP (Kessel 
and Poretz, 2000). The plasma membrane-localized Photofrin® can render the death 
phenotype to be more necrosis like in human epidermoid carcinoma A431 (Hsieh et al., 2003). 
8 
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Besides subcellular localization, light dose also determines the mode of cell death. It 
is believed that a lower dose of light leads to apoptosis, while higher dose leads to necrosis 
(Plaetzer et al.，2002). With the use of the amphiphilic photosensitizer 13,17-bis(l-
carboxypropionyl)carbamoylethyl-8-ethenyl-2-hydroxy-3-hydroxyiminoethylidene-
2,7,12,18-tetramethylporphyrin sodium salt [ATX-S10(Na)], light doses that led to < 70% 
cytotoxicity induced mainly apoptosis in human malignant melanoma cells, while doses 
which led to 99% cytotoxicity induced necrosis (Nagata et al., 2003). 
1.2.2 PDT-induced anti-tumor immunity 
An ideal cancer therapy would destroy not only the primary tumor, but also trigger the 
immune system to recognize, track down and destroy remaining tumor cells (Castano et al., 
2006). A lot of evidence showed that the outcome of PDT is greatly dependent on the 
contribution of host response (Korbelik, 2006). Treatment of tumors by PDT results in an 
oxidative stress at the targeted site associated with a wide range of photooxidative lesions 
produced in the membrane and cytoplasm of cancer cells, tumor vasculature and other stroma 
elements. Tumor destruction is experienced by the host as a local trauma threatening the 
integrity and homeostasis at the affected site. Therefore the host is provoked to launch 
canonical response to deal with the localized injury to prevent spreading of tissue damage, 
remove the dead and damaged tissue and restore tissue function, which are orchestrated by the 
9 
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innate immune system and characterized by the activation of inflammation and acute phase 
response (Korbelik, 2006). The occurrence of inflammation may be induced by expression of 
two transcription factors, nuclear factor KB and activator protein 1，which are known to be 
activated by cellular oxidative stress (Sun and Xiao, 2003). At the therapeutic point of view, 
the host response can amplify the PDT instigated eradication of tumors, which can uncover 
the tumor-specific antigens and lead to their presentation for the recognition and response by 
adaptive immune system targeted to the tumor. In vitro studies showed that PDT can have 
effects on monocyte/macrophage and lymphocyte cell lineage which are easily killed by PDT 
(Castano et al., 2006). In the in vivo studies, inflammatory cytokines and chemokines were 
also detected in the serum of mice that have received PDT directed at a subcutaneous tumor 
or to an area of normal skin (Gollnick et al., 2003). In clinical studies, increased levels of 
interleukin (IL) 1 , 6 , 8 and 10 were also detected in patients after surgery and PDT for 
mesothelioma (Yom et al., 2003). Korbelik et al. (1996) has shown that PDT treatment of 
murine EMT6 mammary sarcoma using Photofrin® and light cured all lesions growing in 
BALB/C mice. In contrast, the same treatment produced initial ablation but no long-term cures 
of EMT6 tumors growing in either Severe Combined Immunodeficiency (SCID) or nude mice, 
which suggested that the activity of host lymphoid populations was essential for preventing 
the recurrence of EMT6 tumors following PDT treatment used in this study. 
10 
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1.3 Clinical applications of PDT 
1.3.1 Photofrin® 
Photofrin® (HpD, porfimer sodium) is commercially available from Axcan Pharma., 
Inc. and has the longest clinical history and patient track record. It remains the most 
common photosensitizer for the treatment of non-dermatological tumors (Brown et al., 
2004). Photofrin® can be easily synthesized by reacting hematoporphyrin in a mixture of 
sulfuric and acetic acids to form hematoporphyrin IX (di- and mono-) acetates. Hydrolytic 
treatment with base yields a crude mixture commonly referred to as HpD. Figure 1.4 shows 
the structure of Photofrin®. Commercially available Photofrin® is made by removing 
components with low-molecular weight. The purified fraction is composed of monomers, 
dimers, trimers and larger oligomers up to eight to nine porphyrin units (MacDonald and 
Dougherty, 2001). A wide variety of neoplasms and even 'benign' lesions can be treated on 
an outpatient basis with Photofrin® (Allison et al , 2004). The advantages of Photofrin® are 
first it destroys tumors effectively; and second it is non-toxic in the absence of light and can 
be easily formulated in a water-soluble preparation for intravenous injection. Since this drug 
has been used for more than 20 years and no long-term safety issues have emerged (Brown 
et al., 2004), Photofrin® does not appear to succumb to multi-drug resistance and has no 
known cumulative dose ceiling as radiation and chemotherapy do. Thus patients can be 
treated repeatedly as needed. 
11 
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—'>1 
Figure 1.4 Structure of Photofrin®, n = 1-9 (Josefsen and Boyle, 2008a) 
Photofrin® is a mixture of hematoporphyrin products with several absorption peaks. 
Since the absorption peak with the longest wavelength at 630 nm is the weakest, a high light 
dose of 100-200 J/cm^ is required for tumor control which always comes with skin 
photosensitivity for 4 to 12 weeks (Triesscheijn et al., 2006). Moreover, since Photofrin® 
also appears to be taken up by other rapidly proliferating tissues like skin, therefore a 
possible complication caused by severe photoreaction such as sunburn or skin rashes might 
be resulted. As a result, patients need to avoid sunlight for about 6 weeks after treatment 
(MacDonald and Dougherty, 2001). 
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1.3.2 Clinical applications of PDT 
Over the past 3 decades, PDT has been proven to be successful in treating different 
types of cancers. Besides, PDT has also been approved for other applications such as wet age-
related macular degeneration which is the major cause of blindness in the aged populations. 
Many approved photosensitizers have been developed for different clinical applications in 
different countries (Table 1.1). Other treatments avenues are also being explored. One 
ingenious idea is photoangioplasty to treat coronary artery disease by using a tiny light source 
to illuminate the artery, particularly targeting at the plaque and destroying it. Due to the 
increasingly widespread diffusion of antibiotic-resistant microbial strains, photodynamic 
antimicrobial chemotherapy (PACT) offers favorable features for the treatment for bacterial, 
fungal, parasitic, and viral infections, such as the broad spectrum of antimicrobial action and 
low risk of developing photoresistant strains. At present, PACT appears to be especially 
convenient for the treatment of localized infections, such as oral candidosis, periodontitis or 
chronic wounds (Calzavara-Pinton et al., 2005; Jori, 2006; Konopka and Goslinski, 2007). In 
our laboratory, previous study was done to investigate the antifungal effect of an bisamino 
silicon(IV) phthalocyanine BAM-SiPc and it was found that BAM-SiPc-PDT is effective in 
killing Candida albicans (So et al., 2009). 
13 
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Table 1.1 Summary of a range of photosensitisers and their clinical applications 
(Josefsen and Boyle, 2008a). 
- MARKETING PRE/CLINICAL COUNTRIES 
IKADEINAME COMPANY APPLICATION APPROVED IN 
~Photofrin QLT Oesophageal, lung, Canada (1993), The 
(sodium porfimer) Phototherapeutics bladder and cervical Netherlands (1994), 
dysplasia; Barrett's Japan (1994), USA 
esophagus (1995), France 
(1996), Germany 
(1997), Finland 
(1999), UK (1999) 
Sweden (2000), 
Italy (2000), Ireland 
(2000), Poland 
(2000) 
Tevulan (5- DUSA Actinic keratosis, USA (1999), 
aminolevulinic acid) Pharmaceuticals actinic keratosis and Sweden (2001), 
basal cell carcinoma Europe (2001), 
Korea (2007) 
"Visudyne QUf Wet aged- re la tedEurope (2001), USA 
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1.3.3 Challenges of PDT for clinical applications 
PDT offers several advantages over conventional therapies. In contrast to weeks or 
months of radiotherapy or chemotherapy or prolonged hospitalization of surgery, PDT 
offers an advantage of being an outpatient therapy. PDT can induce immune response and 
provide long term control of tumor growth. It is also cost-effective and has high cure rates. 
However, acceptance of PDT is still limited by the high cost of setup, lack of standardized 
protocol from randomized trials, limited accessibility to deep-penetrated tumors and 
possibility of photosensitivity over a long period following treatment. To realize the 
popularity of PDT, more efforts should be done to overcome the above challenges. Another 
limitation of conventional PDT approach for cancer treatment is its lack of selectivity 
towards tumor tissues in terms of cellular localization and cytotoxicity. The ideal 
photosensitizer should enable selective accumulation within the tumor tissue. Unfortunately, 
the majority of the photosensitizers are taken up non-specifically by all cell types. Therefore, 
in recent years, lots of efforts have been spent to improve the specificity of the 
photosensitizers for more effective therapeutic outcomes and less side-effects. Many new 
second and third generation photosensitizers are being synthesized in an attempt to create 
more specific photosensitizers (Triesscheijn et al.，2006). 
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1.4 The development of new photosensitizers 
1.4.1 Targeted PDT 
One major obstacle for the development of PDT is its lack of specificity to tumor 
tissues. For the treatment of tumors, a widespread uptake of photosensitizers has limited its 
ability to target specifically to localized lesions in the body. Photosensitizers may accumulate 
in the skin and lead to photosensitivity. Therefore, in order to reach the full potential of PDT, 
there is a need for numerous targeting motifs so that tumor tissues can be selectively 
destroyed. A lot of efforts have been spent on the development of photosensitizers which can 
be more specifically targeted to malignant tissues and increase the uptake of the dye by target 
cells. One approach is to conjugate photosensitizers with biomolecules. Conjugating 
photosensitizers with saccharides such as glucose and galactose can prevent aggregation of 
photosensitizers, increase their water solubility and biological efficacy (Maillard et al., 1989). 
Our laboratory has previously described the preparation of silicon(IV) phthalocyanine 
conjugated to galactose via axial coordination and found that this compound is highly soluble 
in most organic solvents and remains essentially non-aggregated in solution. Moreover, it 
shows an improvement in cellular uptake which may explain its high photocytotoxicity 
against the hepatocarcinoma (HepG2) cells (Lee et a l , 2005). 
Targeted PDT can also be achieved via receptor-mediated delivery system, such as via 
low-density lipoproteins (LDL), gastrin-releasing peptide and epidermal growth factor (EGF) 
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receptors. LDL is an attractive vehicle for drug targeting, since highly proliferating tumor 
cells overexpress LDL receptors. Previous study has reported that the reconstituted LDL-
naphthalocyanine is able to maintain the size and shape of native LDL, retain their LDL 
receptor-mediated uptake by cancer cells and has a preferential uptake by tumor vs normal 
tissue in vivo (Song et al., 2007). Another study has shown that by conjugating aluminum 
phthalocyanine tetrasulfonate AlPcS(4) with bombesin (gastrin-releasing peptide) and 
targeting it to gastrin-releasing peptide receptor which is early expressed in prostate tumor 
development, the in vitro photodynamic efficacy against human prostate cancer cells can be 
improved by 2.5 fold over the non-conjugated AlPcS(4) (Dubuc et al., 2008). 
Photoimmunotherapy combines phototoxicity of the photosensitizers with the 
selectivity of monoclonal antibodies directed against tumor-associated antigens by 
conjugating multiple photosensitizers with antibody fragments (scFvs). The treatment of 
human breast cancer xenografts with a photoimmunoconjugate comprising an anti-epidermal 
growth factor 2 (anti-HER2) receptor 2 scfV linked to 8-10 molecules of pyropheophorbide a 
leads to significant tumor regression (Bhatti et al., 2008). Hemotoporphyrin conjugated with 
antibodies with vascular endothelial growth factor (VEGF) was also previously synthesized 
and this conjugate exhibited a stronger anti-tumor effect in vivo when compared with the 
native hematoporphyrin. The development of cellular characteristics wi l l eventually lead to 
the discovery of targeting mechanisms (Novichenko et al., 2008). Research is still ongoing to 
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develop various photosensitizers and numerous targeting motifs so that each disease type can 
be targeted on an individual basis (Sharman et al., 2004). 
Carriers for drug such as liposomes and nanoparticles are also made possible to 
enhance efficacy of photosensitizers (Chatterjee et al., 2008; Sibani et al., 2008). Previous 
study has shown that encapsulating methylene blue in nanoparticles can increase its nuclear 
localization and result in enhanced DNA damage, which significantly potentiate the 
cytotoxicity of methylene blue-mediated PDT (Khdair et al., 2008). Nishiyama et al. (2009) 
showed that the dendrimer phthalocyanine with polymeric micelle (DPc/m) can efficiently 
induce cell death and significantly enhance in vivo antitumor efficacy, when compared with 
the dendrimer phthalocyanine without polymeric micelle (DPc), indicating that polymeric 
micelle can be an effective nanocarrier for drug delivery. 
1.4.2 Phthalocyanine 
Phthalocyanine has been extensively examined as photosensitizers. They are 
synthesized by joining four benzene rings to the p-pyrrolic positions of porphyrins and 
substituting methane-bridge carbons with nitrogen (Figure 1.5). Polar substituents are often 
linked to avoid solubility problems caused by their strong hydrophobicity. The presence of 
aluminium, zinc(II), silicon(IV) and other ions gives hexacoordination and guarantees a 
satisfactory yield of singlet oxygen generation (Calzavara-Pinton et al., 2007). The 
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photophysical properties of phthalocyanine are of utmost interests since they exhibit very 
strong absorption at longer wavelengths than porphyrins as they have a larger macrocycle 
ring system (Miller et al., 2007). With a very strong absorption peak in the far-red region of 
the visible spectra, tissue penetration can be improved. Apart from its non-aggregated 
nature, phtahlocyanine does not exist as structural isomers (Lo et al., 2004). Its chemical 
synthesis and structure allow the addition of substituents to both the central metal and the 
periphery of the hydrophobic phthalocyanine macrocycle to change its physical properties 
which determine its cellular uptake, subcellular localization and phototoxicity (Allen et al., 
2002). 
Q v v p 
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Figure 1,5 Structure of phthalocyanine (Josefsen and Boyle, 2008a) 
Besides having desirable physical properties, phthalocyanine also exhibits high 
photodynamic activities, both in vitro and in vivo, against a range of model cancer cell lines 
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and tumors. Bis(cholesteryloxy) derivative of silicon(IV) phthalocyanine exhibits half lethal 
dose at 6-8 nM via early activation of mitochondria-mediated apoptosis (Barge et al., 2004). 
In our laboratory a number of silicon(IV) and zinc(II) phthalocyanines were synthesized. 
Most of them possess desirable physical properties and potent photodynamic activities in 
killing cancer cells (IC50 ranged from 0.03 to 4.7|iM against both HepG2 and HT29) (Choi 
et al., 2008; Liu et al., 2009; Lo et al., 2008). 
Silicon(IV) phthalocyanines are also effective in the treatment of SW480 human 
colon cancer xenografts and skin papillomas in in vivo studies (Kalka et al., 2000; Whitacre 
et al., 2000). They have been studied in clinical applications. Phase I clinical trials have 
been performed and the preliminary results were promising with a subset of patients 
responded to therapy showing improvement in the treated lesions, as evidenced by the 
thinning and decreased erythema. Both the responders and non-responders tolerated the 
treatment well, with no side effects or pain reported (Miller et al., 2007). 
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1.5 Objective of my study 
Over the past few years, a number of modified phthalocyanines have been studied in 
our laboratory. SiPcGlu (Figure 1.6) was chosen for the present study as it is one of the 
most potent phthalocyanines. Human colorectal adenocarcinoma HT29 was used to study its 
photocytotoxicity. It is believed that the action mechanism of PDT is via the production of 
ROS. Therefore, the production of ROS after SiPcGlu-PDT and its role in triggering cell 
death by the use of various antioxidants were investigated. Furthermore, the mode of cell 
death initiated by SiPcGlu-PDT was also evaluated. Since the subcellular localization of 
photosensitizer determines the primary site of photodamage and cell death pathways, 
confocal microscopic investigations with the use of organelle-specific probes were 
performed to study the intracellular localization of SiPcGlu. 
To evaluate whether SiPcGlu has the potential for clinical PDT, a HT29 tumor-
bearing nude mice model was developed to investigate the in vivo efficacy of SiPcGlu-PDT 
to eradicate tumor. Biodistribution of SiPcGlu was also performed to investigate whether its 
glucose moiety can target it to tumor specifically, through the over-expressed glucose 
transporters (GLUTS) in cancer cells. Finally, the safety use of the drug was evaluated by 
analyzing levels of plasma enzyme markers for any possible hepatic or cardiac injuries. 
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Figure 1,6 Chemical Structure of SiPcGlu 
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2.1 Synthesis of glucoconjugated silicon(IV) phthalocyanine 
(SiPcGlu) 
SiPcGlu was kindly provided by Prof. Dennis K.P. Ng from the Department of 
Chemistry, The Chinese University of Hong Kong. The procedures of the synthesis were 
summarized as follow. A mixture of silicon phthalocyanine dichloride (1.02 g, 1.7 mmol), 
protected glucose (3.73 g, 8.6 mmol) and NaH (60% in mineral oil, 0.83 g, 20.8 mmol) in 
toluene (80 mL) was refluxed for 2 days. After evaporating the solvent in vacuo, the residue 
was subjected to column chromatography on neutral alumina using CHCI3 as eluent, 
followed by gel permeation chromatography using THF as eluent. The crude product was 
then chromatographed again on neutral alumina using CH2CI2, and then CHCI3/CH2CI2 (1:4) 
as eluent. The product (0.3 g, 0.22 mM) was collected as a blue solid. The product yield is 
13% from the precursor silicon phthalocyanine dichloride. The purity of the product is 
confirmed by proton nuclear magnetic resonance NMR) spectroscopy and elemental 
analysis. 
2.2 In vitro studies 
2.2.1 Cell line and culture conditions 
The human colorectal adenocarcinoma HT29 cells were originally obtained from 
American Type Culture Collection (ATCC Number: HTB-38). They were maintained in 
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Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine 
serum, 100 units/ml penicillin, 100 |ag/ml streptomycin, 2 mM L-glutamine and 10 |ig/ml 
transferrin (Sigma-Aldrich, USA) in 5% CO2, 95% air in a humidified incubator at 37 °C. 
Al l reagents were purchased from Invitrogen, USA unless otherwise specified. 
2.2.2 Photodynamic treatment 
SiPcGlu was first dissolved in N,N-dimethylformamide (DMF, Sigma-Aldrich) to 
give a 1.5 mM solution and then diluted to 80 | iM with an aqueous solution of Cremaphor 
EL (0.047g/ml in water, Sigma-Aldrich). The solution was then filtered with 0.2 |im 
Acrodisc® Syringe Filters with Supor® Membrane (Pall Gelman Laboratory, USA) and then 
diluted to appropriate concentrations with culture medium. For the photodynamic treatment 
with Photofrin®, Photofrin® was dissolved in culture medium directly. Cells (3 x 10"^ ) were 
seeded in each well of the 96-well plates and incubated overnight in 5% CO2, 95% air in a 
humidified incubator at 37 °C. After incubation, the cells were rinsed with 100 \i\ phosphate 
buffered saline (PBS). Different concentrations of SiPcGlu (100 |il) were added to each well 
and incubated for 2 h in 5% CO2, 95% air in a humidified incubator at 37 °C in darkness. 
The cells were then rinsed with PBS and refed with 100 |il culture medium, followed by 
illumination for 20 min with a 300 W halogen lamp through a color glass filter (Newport, 
USA) which cuts off light below 610 nm so that only a narrow region of light (at ca. 610-
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700 nm) can be absorbed by the compound to initiate the photodynamic action (Figure 1.2). 
'•s 
The fluence rate for the illumination was 40 mW/cm so that an illumination of 20 min wi l l 
2 
lead to a total fluence of 48 J/cm . 
6 
300W Halogen lamp 
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Figure 2.1 Schematic diagram showing the setup for illumination of the HT29 cells 
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2.2.3 Cell viability assay 
After photodynamic treatment, the cells were incubated for 24 h in 5% CO2, 95% air 
in a humidified incubator at 37 °C in darkness. After incubation, the cell viability was 
determined by the colorimetric 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT, USB Corporation, USA) assay. The PDT-treated cells were first rinsed with 
PBS. MTT solution (50 3 mg/ml in PBS) was then added to each well followed by 
incubation for 2 h in 5% CO2, 95% air in a humidified incubator at 37 °C in darkness. 
Afterwards, 50 |il sodium dodecyl sulfate (SDS, 10% w/v, USB) was added to each well. 
The plate was incubated for 30 min in an oven at 60 °C to lyse the cells, and then 80 |il iso-
propanol was added to dissolve the purple formazan crystal formed inside the cells. The 
plate was agitated on a Microplate Reader (Model number: 3550, Bio-rad, USA) at room 
temperature for 10 s and the absorbance of 540 nm was taken. The average absorbance of 
the blank wells, which did not contain the cells, was subtracted from the readings of other 
wells. The cell viability was then determined by the following equation: 
0/0 Viability = (OD540(treated cells) " OD540(blank) ! (OD540(control) " OD540(blank)) X 100% 
2.2.4 Light dose effect on the photocytotoxicity of SiPcGlu-PDT 
Halogen lamp and a diode laser were used to study the effect of light dose or light 
source on the cytotoxicity induced by SiPcGlu-PDT. For halogen lamp, the fluence rate for 
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the illumination was 40 mW/cm so that an illumination of 20 min wi l l lead to a total 
fluence of 48 J/cm^. For diode laser, continuous wave laser was generated from the Ceralas 
PDT 675 medical laser system (bandwidth 675 nm 士 3 nm, power range 0.1 - 1 W) coupled 
with a frontal light distributor (CeramOptec GmbH, Germany) (Figure 2.2). The fluence 
rate for illumination was 200 mW/cm and the time for illumination is 10 and 40 s to give a 
total fluence of 2 and 8 J/cm^ respectively. 
Figure 2,2 Setup of the PDT laser system 
28 
Chapter 2 Materials and Methods 
2.2.5 Determination of reactive oxygen species (ROS) production 
by SiPcGlu-PDT 
ROS production during SiPcGlu-PDT was determined by using 2',7'-
dichlorofluorescein diacetate (DCFDA, Molecular Probes, USA). Cells were incubated with 
various concentrations of SiPcGlu. After rinsing with PBS, 100 [i\ of 10 [ M DCFDA was 
added to each well followed by incubation for 30 min in 5% CO2, 95% air in a humidified 
incubator at 37 °C in darkness. The cells were then illuminated for 20 min with the halogen 
lamp. Fluorescence measurements were made by fluorescence plate reader (TECAN 
Polarion, UK) with 485 nm excitation and 535 nm emission filters. 
2.2.6 Effect of antioxidants on the photocytotoxicity of SiPcGlu-
PDT 
To determine the effects of antioxidants on the photocytotoxicity induced by 
SiPcGlu-PDT, final concentrations of 50 m M D-mannitol, 200 | iM vitamin C or 100 | iM L-
histidine (all purchased from Sigma-Aldrich) were added and incubated with different 
concentrations of SiPcGlu for 2 h，followed by illumination with halogen lamp to trigger 
photodynamic reactions. After 24 h, cell viability was determined by MTT assay. 
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2.2.7 Determination of reactive oxygen species (ROS) production 
after SiPcGlu-PDT 
To determine the ROS production after PDT, the cells were rinsed with PBS 
immediately after illumination with halogen lamp. DCFDA was then added to each well, 
followed by incubation in 5% CO2, 95% air in a humidified incubator at 37 °C in darkness 
for 1 h. Fluorescence measurements were made by fluorescence plate reader. 
2.2.8 Glucose competitive assay 
The potential role of GLUTS in the uptake of the photosensitizer was studied by a 
glucose competitive assay. Glucose solutions (1 or 100 mM in PBS) were added and 
incubated with different concentrations of SiPcGlu formulated in PBS for 2 h, followed by 
rinsing with PBS. The same experimental setup with halogen lamp was used for 
illumination of the cells. After 24 h, cell viability was determined by MTT assay. 
2.2.9 Terminal deoxynucleotidyl transferase-mediated dUTP 
nick end labeling (TUNEL) assay 
Cells (1 X 106) were seeded in 35 mm tissue culture dish and incubated overnight in 
5% CO2, 95% air in a humidified incubator at 37 °C. After incubation, the cells were rinsed 
with 100 PBS. Different concentrations of SiPcGlu (1 ml) were added to each dish and 
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incubated for 2 h. The cells were rinsed with PBS and refed with culture medium, followed 
by illumination with halogen lamp. Twenty-four h after PDT, the presence of DNA breaks 
were detected by using the In Situ Cell Death Detection Kit, Fluorescein (Roche, Germany) 
according to the manufacturer's instructions. In brief, the cells were trypsinized, washed 
with PBS for 3 times, resuspended in 100 |il of 2% Fixation Solution (4% paraformaldehyde 
in PBS, pH 7.4) and incubated for 60 min at room temperature with gentle shaking to avoid 
cell clumping. The cells were then centrifuged at 300 g for 10 min to remove the fixative 
and rinsed with PBS twice. Afterwards, the cells were resuspended in Permeabilization 
Solution (0.1% Triton-X in 0.1% sodium citrate) for 2 min on ice and washed with PBS 
twice. Finally the cells were labeled with 50 pi TUNEL reaction mixture and further 
incubated for 60 min at 37 °C in darkness. The 488 nm laser was used for excitation. The 
samples were then analyzed by the FITC channel of the BD FACSCanto™ flow cytometer 
(Becton Dickinson, USA) and 10,000 cells were counted. The data were analyzed with the 
Program WinMDI. 
2.2.10 DNA fragmentation analysis by gel electrophoresis 
Twenty-four h after PDT, the cells were trypsinized and washed with PBS for three 
times. The cells were lysed in 400 ^il lysis buffer (200 mM Tris-HCl, pH 8.3, 100 mM 
EDTA, 1% SDS). After adding 20 \i\ of 10 mg/ml proteinase K (USB), the cells were 
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incubated at 37 °C for 2 h to digest the protein. The samples were then cooled to room 
temperature. Saturated NaCl (150 lal) was added and mixed by vigorously shaking the tube 
followed by centrifugation at 2,700 g at room temperature for 15 min. One ml of cold 
absolute ethanol was added to the supernatant and they were mixed by inverting the tubes. 
DNA was centrifuged out at 20,817 g at 4 °C for 20 min and the DNA pellet was washed 
with 70% ethanol and allowed to dry in oven. DNA was resuspended in 20 |il TE buffer (10 
mM Tris-HCl, pH 8.0, 1 mM EDTA) containing 0.2 mg/ml RNase (Roche) and incubated at 
37 °C for 90 min. One [ig of DNA preparation was loaded into each lane of a 2% agarose 
(USB) gel containing ethidium bromide (0.4 |ig/ml). Electrophoresis was carried out at 90 
V for 2 h. Image of gel was captured with a Multilmage™ Light Cabinet (Alpha Innotech 
Corporation, USA). 
2.2.11 Annexin-V & propidium iodide staining assay 
Twenty-four h after PDT, the cells were trypsinized and washed with PBS for three 
times and then resuspended in 0.5 ml I X binding buffer (0.01 M HEPES/NaOH, pH 7.4， 
140 mM NaCl, 25 m M CaCb). The cells were labeled with 5 |li1 Annexin V solution (BD 
P h a r m i n g e n ™， U S A ) as well as 4 |ag/ml propidium iodide solution (Sigma-Aldrich) and 
allowed to incubate at room temperature in darkness for 15 and 5 min respectively. The 
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fluorescence of the cells was analyzed with a dot plot (PE vs FITC) of the BD 
FACSCanto™ flow cytometer and 10,000 cells were counted. 
2.2.12 Subcellular localization studies 
Cells (3 X 10^) were seeded in a 35 mm glass bottom culture dish (MatTek, USA). 
The cells were first rinsed with PBS and incubated with 0.5 | iM SiPcGlu for 90 min. The 
cells were then stained with 200 nM MitoTracker® Green FM, 10 |j.M ER-Tracker^^ Green, 
2 [ iM BODIPY® FL C5-ceramide or 4 | jM LysoTracker® Green Probes (all purchased from 
Molecular Probes) for 30 min. After rinsing with PBS, the cells were refed with culture 
medium and viewed with Leica SP5 Confocal Laser Scanning Microscope (Leica 
Microsystems GmbH, Germany). The argon/krypton laser with a wavelength of 488 nm and 
the helium/neon laser with a wavelength of 633 nm were used to excite the organelle-
specific probes and SiPcGlu respectively. A water immersion objective with magnification 
of 63 was used for image capturing. Their emitted fluorescences (at 516 nm for organelle-
specific probes and 673 nm for SiPcGlu) were captured and further analyzed by using LAS 
AF software. The subcellular localization of SiPcGlu was revealed by drawing the 
fluorescence intensity profiles of SiPcGlu and the organelle-specific probes. 
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2.2.13 Detection of mitochondrial superoxide production 
Immediately after SiPcGlu-PDT, 5 | iM MitoSOX™ Red mitochondrial superoxide 
indicator (Molecular Probes) was added to stain the cells for 30 min. After incubation, the 
cells were trypsinized and washed in PBS for three times. The emitted fluorescence due to 
superoxide production in mitochondria was detected by the PE channel of the BD 
FACSCanto™ flow cytometer and 10,000 cells were counted. 
Alternatively, 3x10^ cells were seeded in 35 mm glass bottom culture dish and after 
PDT, the cells were labeled with 5 ^iM MitoSOX™ Red mitochondrial superoxide indicator 
for 15 min and washed with PBS for 3 times and re-fed with culture medium. The cells 
were viewed with Leica SP5 Confocal Laser Scanning Microscope. MitoSOX™ Red was 
excited by argon/krypton laser with wavelength of 514 nm. The emitted fluorescence was 
detected at 580 nm. 
2.2.14 Assessment of mitochondrial membrane potential 
After PDT, the cells were trypsinized and washed with PBS for three times followed 
by resuspension in 1 ml culture medium. The cells were then stained with 2 \ iM JC-1 
staining solution (Molecular Probes) and incubated at 37 °C. The cells were then pelleted by 
centrifugation and resuspended in 500 |il PBS. Mitochondrial depolarization is indicated by 
the decrease in the red/green fluorescence ratio which can be analyzed with a contour plot 
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(PE vs FITC) of the BD FACSCanto™ flow cytometer. The data were analyzed with the 
Program WinMDL 
2.2.15 Caspase-3 activity assay 
The activation of caspase-3 can be detected by a commercially available caspase-3 
assay kit (BD Pharmingen^'^). The assays were done according to the manufacturer's 
instructions. Twenty-four h after PDT, the cells were trypsinized and washed with PBS for 
three times followed by resuspension in 200 [i\ cold cell lysis buffer and incubation on ice 
for 30 min. For each sample, 15 |i l reconstituted N-acetyl-Asp-Glu-Val-Asp-7-amino-4-
methylcoumarin (Ac-DEVD-AMC) was added to the tube containing 1 ml I X HEPES 
buffer. Cell lysate (100 fil) was added to the mixture and incubated for 1 h at 37 °C. For 
inhibitor control, the cells were treated with 12nM SiPcGlu-PDT and 20 |ig/ml Ac-DEVD-
CHO，a synthetic inhibitor of caspase-3 activity. The amount of AMC liberated from Ac-
DEVD-AMC by active caspase-3 was measured using a fluorescence spectrofluorometer 
(Perkin Elmer, USA) with excitation and emission wavelengths of 380 and 440 nm 
respectively. 
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2.2.16 Western blot analyses for cytochrome c, caspase-3, PARP 
and glucose-regulated protein 78 (GRP78) 
Twenty-four h after PDT, the cells were trypsinized and washed with PBS for three 
times. For the analysis of cytochrome c, the Cytosol/Particulate Rapid Separation Kit 
(BioVision, USA) was used to obtain the cytosolic fraction, according to the manufacturer's 
instructions. For the analyses of caspase-3, poly (ADP-ribose) polymerase (PARP) and 
GRP78, whole cell lysate was used. Cells (4 x 10^) were incubated in 50 |il lysis buffer [75 
mM NaCl, 1 mM NaH2P04, 250 mM sucrose, 8 mM Na2HP04 and 4 |il protease inhibitor 
cocktail (Sigma-Aldrich)] in the presence of 8 ^ig/jj^l digitonin (Sigma-Aldrich) and then 
vortexed immediately for 30 s. The whole cell lysate was obtained by centrifugation at 
20,817 g for 1 min at 4 For electrophoresis, 25 |j,g protein (determined by the 
bicinchoninic acid method) per lane was mixed with sample buffer (65.5 mM Tris-HCl, pH 
6.8, 0.11% glycerol, 2.1% SDS, 2.6% p-mercaptoethanol and 0.13% bromophenol blue) in a 
12% polyacrylamide gel with 5% stacking gel. After electrophoresis, the proteins were 
transferred to immobilon-P transfer membrane (Millipore, USA) using a semi-dry transfer 
system (Bio-rad). Membranes were blocked with 5% skim milk in TBS-T (TBS with 0.1% 
Tween-20). Target proteins were incubated with mouse monoclonal antibodies against 
cytochrome c (1:1000, BD Pharmingen^^) and caspase-3 (1:500, Zymed, USA), rabbit 
polyclonal antibodies against GRP78 (1:200, Santa Crux Biotechnology, USA) and PARP 
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(1:200, Santa Cruz) for 18 h at 4 and rabbit polyclonal antibodies against p-actin 
(1:1000, Sigma-Aldrich) for 2 h at room temperature. After several washes with TBS-T, the 
signal was developed by incubating with anti-mouse or anti-rabbit horseradish peroxidase-
conjugated secondary antibodies (1:1000, Amersham Bioscience, USA) for 1 h. Enhanced 
chemiluminescence detection reagents (Amersham Pharmacia, England) were used for 
detecting the signal. 
2.2.17 Ca2+ release from endoplasmic reticulum (ER) 
After PDT, the cells were trypsinized and washed with PBS for three times followed 
by incubation with 2.5 ^iM Fluo-3, A M (Molecular Probes) for 60 min at 37 °C. Before 
fluorescence measurements, cells were washed with culture medium to remove any dye that 
is nonspecifically associated with the cell surface, and then incubated for 30 min to allow 
complete de-esterification of intracellular A M esters. The emitted fluorescence due to Ca^^ 
release from ER was then detected by FITC channel of the BD F A C S C a n t o T M flow 
cytometer and the data were analyzed with the Program WinMDL 
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2.3 In vivo studies 
2.3.1 HT29 tumor-bearing nude mice model 
The nude mice (20 - 25 g) were obtained from the Laboratory Animal Services 
Centre (LASEC) at The Chinese University of Hong Kong. A l l experiments on tumor-
bearing nude mice were approved by the Animal Experimentation Ethics Committee, The 
Chinese University of Hong Kong. Mice were bred under pathogen-free condition with free 
access of food and water. In developing the tumor model, HT29 cells (1 x 10^) were 
subcutaneously inoculated at the back of the nude mice. Measurement of the tumor size 
started on Day 8 after inoculation of tumor cells (Figure 2.3). Three parameters of the tumor, 
viz. length, width and thickness, were measured by micrometer digital caliper (SCITOP 
Systems, Hong Kong). The tumor volume was calculated by the following formula: 
Tumor volume = 71 x (Length x Width x Thickness) / 6 
Figure 2.3 HT29 tumor- bearing nude mice (8 days after inoculation). 
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2.3.2 In vivo photodynamic treatment 
On day 9, SiPcGlu (1 jimole/kg body weight, 0.2 ml) was intravenously injected into 
the tail vein of the tumor-bearing nude mice. Twenty-four h after the injection, laser was 
spotted onto the tumor with a fluence rate of 0.1 W/cm^ for 5 min, giving a total fluence of 
30 J/cm^. Tumor size of the nude mice were followed for the next 15 days. 
2.3.3 Biodistribution of SiPcGlu 
SiPcGlu (1 |imole/kg body weight, 0.2 ml) was intravenously injected into the 
tumor-bearing nude mice. After 24 h, the mice were anesthetized with an intra-peritoneal 
injection of 0.2 ml ketamine/xylazine cocktail solution (0.1 mg ketamine and 0.01 mg 
xylazine/g body weight). The major organs/tissues of the mice were excised, rinsed with 
PBS and blotted dry. The excised organs/tissues were homogenized with DMF (10-fold 
volume of the organs/tissues) by a Biospec Biohomogenizer (Fisher Scientific, USA). 
Homogenates were centrifuged at 2,450 g for 20 min to remove the large debris. 
Supernatants were collected and subjected to fluorescence measurement. The peak 
fluorescence intensity was recorded by scanning the fluorescence emission spectrum from 
610 nm to 900 nm using an excitation wavelength at 608 nm with a fluorescence 
spectrofluorometer (Perkin Elmer, USA). Amount of SiPcGlu present in the sample was 
determined with reference to the standard curves in different organs/tissues. The amount 
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was expressed in % initial dose (% ID) per gram of tissue as calculated by the following 
formula. 
% ID per gram of tissue = (amount of SiPcGlu / weight of the tissue) ^ ^ Oqo/ 
Initial injection dose 
Ketamine and xylazine solution were obtained from LASEC，The Chinese 
University of Hong Kong. 
2.3.4 Assay for plasma enzyme activities 
Blood was obtained by intra-cardiac puncture with a heparinized syringe. Heparin 
(1250 USP units/ml, Sigma-Aldrich) was added to prevent blood coagulation. The blood 
samples were centrifuged at 1,700 g for 5 min to obtain the supernatant which represents the 
plasma. The activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) 
(both purchased from Thermo Electron Corporation, Australia) and creatine kinase (CK, 
Biosystems, Spain) were assayed by the commercially available assay kits. Fifty |il plasma 
was added to 1 ml of ALT, AST and CK assay reagents. Enzyme activities were then 
determined by monitoring the absorbance change at 340 nm for 3 min. The enzyme activity 
was expressed as U/L. 
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2.4 Statistical analysis 
Differences in the tumor volume and caspase-3 activity were analyzed for 
significance by One-way Analysis of Variance (ANOVA, with Holm-Sidak method) and 
Student's Mest respectively. Difference between the values was considered significant 
whenp < 0.05. A l l statistical analysis was done by SigmaStat (Systat Software, San Jose). 
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Chapter 3 Results 
3.1 In vitro studies 
3.1.1 SiPcGlu-PDT induced cytotoxicity on HT29 cells 
In order to investigate the in vitro photocytotoxicity induced by the SiPcGlu-PDT 
and see whether it is essentially non-toxic to the HT29 cells in darkness, the cell survival 
after SiPcGlu-PDT was determined by MTT assay at 24 h post irradiation. Figure 3.1 shows 
the cell survival curves of HT29 after treatment with SiPcGlu-PDT, in the presence or 
absence of red light illumination. From the cell survival curve of HT29 in the absence of 
light, the cell survival was unaffected and remained -100%. The cell survival of HT29 cells 
in the solvent itself is also unaffected with a viability of 91.23 士 1.960/0. On the contrary, in 
the presence of red light, the cell survival of HT29 was significantly reduced in a dose-
dependent manner and the IC50 and IC90 values are about 6 and 12 nM respectively. 
To compare the efficacy of SiPcGlu with that of Photofrin®, the HT29 cells were 
treated with Photofrin®, in the presence or absence of light, using the same experimental 
setup. In the absence of light, the cell survival of HT29 was unaffected and remained 
-100%. However, in the presence of light, Photofrin®-PDT produced a dose-dependent 
cytotoxicity on HT29 cells. The IC50 value is 〜5 jig/ml (Figure 3.2). When compared with 
the IC50 of SiPcGlu-PDT 6 nM, i.e. 7.8 ng/ml, SiPcGlu-PDT is much more potent than 
Photofrin® in killing HT29. 
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Figure 3.1 SiPcGlu-PDT-induced cytotoxicity in HT29 cells. The cells were treated with 
different concentrations of SiPcGlu in the presence ( # ) or absence ( 〇） o f light 
illumination with halogen lamp (48 J/cm^). Cell viability was determined by MTT assay. 
The data are Mean 土 S.E.M. from three independent experiments, each performed in 
quadruplicates. 
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Figure 3.2 Photofrin®-PDT-induced cytotoxicity in HT29 cells. The cells were treated 
with different concentrations of Photofrin® in the presence ( # ) or absence (〇）of light 
illumination with halogen lamp (48 J/cm^). Cell viability was determined by MTT assay. 
The data are Mean 士 S.D., n = 4. 
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3.1.2 Light dose effect on cytotoxicity by SiPcGlu-PDT 
Halogen lamp and diode laser were used to study the effect of light dose on the 
photocytotoxicity induced by SiPcGlu-PDT. A total fluence of 48 J/cm^ was delivered to 
the cells with halogen lamp. For diode laser, 2 light doses, 2 and 8 J/cm^ were used. With a 
total fluence of 8 J/cm^, the IC50 produced by the diode laser was similar to that produced 
by the halogen lamp. By reducing the total fluence to 2 J/cm^, the photoactivity was 
lowered, giving an IC50 value of 46 nM (Figure 3.3). 
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Figure 3.3 Light dose effect on photocytotoxicity induced by SiPcGlu-PDT. After 
incubating the cells with SiPcGlu, the cells were illuminated with halogen lamp of 48 J/cm^ 
( • ) or a diode laser of 2 ( • ) or 8 J/cm^ (〇）.Cell viability was determined by MTT assay. 
The data are Mean 土 S.E.M. from three independent experiments, each performed in 
quadruplicates. 
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3.1.3 SiPcGlu-PDT induced ROS production 
To study the action mechanism of SiPcGlu-PDT in triggering cell death, the 
SiPcGlu-treated cells were subjected to DCFDA staining to investigate the ROS production 
during photodynamic treatment. Figure 3.4 shows the ROS production curves in the 
presence or absence of red light illumination. In darkness, the ROS production was 
unaffected while in the presence of light, the ROS production was increased in a dose-
dependent manner and had 〜4-fold increase at concentration of ca. 30 nM. 
3.1.4 SiPcGlu-PDT induced cell death through Type I and II 
photoreactions 
In order to investigate whether Type I or Type II reactions are involved in the 
photodynamic action by SiPcGlu-PDT, the hydroxy 1 radical scavenger D-mannitol and 
singlet oxygen scavengers L-histidine and vitamin C were used to investigate whether they 
can protect the cells from photocytotoxicity. HT29 cells were pretreated with antioxidants 
and SiPcGlu and subjected to light illumination. Their cell viabilities were determined. The 
cell survival curves show that both the hydroxyl radical and singlet oxygen scavengers can 
slightly protect the cells from photodamage (Figure 3.5), indicating that SiPcGlu-PDT 
triggers cell death via both Type I and Type I I photoreactions. 
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Figure 3.4 SiPcGlu-PDT-induced ROS production. The cells were incubated with 
different concentrations of SiPcGlu, followed by staining with DCFDA in the presence ( # ) 
or absence (〇）of light illumination with halogen lamp (48 J/cm^). ROS production was 
determined by using a fluorescence plate reader with excitation and emission filters at 485 
and 535 nm respectively. The data are Mean 土 S.E.M. from three independent experiments, 
each performed in quadruplicates. 
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Figure 3.5 SiPcGlu-PDT-induced cell death via Type I and Type II photoreactions. 
Antioxidants were added to HT29 cells and incubated with different concentrations of 
SiPcGlu. The 4 groups of treatments included no antioxidant control ( # ) , and cells treated 
with 50 mM D-mannitol (〇)，100 | iM L-histidine ( • ) and 200 | iM vitamin C ( • ) . The 
cells were illuminated with halogen lamp (48 J/cm^). Cell viability was determined by MTT 
assay. The data are Mean 土 S.E.M. from three independent experiments, each performed in 
quadruplicates. 
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3.1.5 ROS production after SiPcGlu-PDT 
Zorov et al. (2000) have reported that the photodynamically produced ROS causes 
post-PDT ROS production inside the cells. Therefore, to study whether ROS was produced 
after SiPcGlu-PDT，DCFDA was added to the HT29 cells after SiPcGlu-PDT, followed by 
1 hr incubation. Figure 3.6 shows that after SiPcGlu-PDT, there is a dose-dependent 
increase in ROS production. Since mitochondria is a major source of endogenous ROS 
which may be related to respiratory chain, investigation was performed to see whether 
oxidative insult caused by SiPcGlu-PDT leads to interrelated intramitochondrial generation 
of superoxide anion and other ROS (Mukhopadhyay et al., 2007). We applied M i t o S O X ™ 
Red mitochondrial superoxide indicator which allows highly selective and quantitative 
detection of superoxide in the mitochondria of live cells by flow cytometry. Result shows 
that after SiPcGlu-PDT, there is a significant increase in mitochondrial superoxide 
production in a dose-dependent manner (8.82 土 2.97o/o for control cells; 18.61 土 1.15o/o and 
43.85 士 6.310/0 in 6 nM and 12nM SiPcGlu-PDT-treated cells respectively) (Figure 3.7). 
The mitochondrial ROS production can further be confirmed by staining the cells with 
MitoSOX™ Red and using confocal microscopy. Confocal microscopic imaging shows a 
significant increase in mitochondrial fluorescence intensity of Mi toSOX™ Red in HT29 
after 12 nM SiPcGlu-PDT (Figure 3.8), which is in agreement with the results by flow 
cytometric measurement. 
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Figure 3.6 ROS production after SiPcGlu-PDT, The cells were treated with different 
concentrations of SiPcGlu. After light illumination, the cells were stained with DCFDA for 
1 h. ROS production was determined by using a fluorescence plate reader with excitation 
and emission filters at 485 and 535 nm respectively. The data are Mean 土 S.E.M. from 
three independent experiments, each performed in quadruplicates. 
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Figure 3.7 SiPcGlu-PDT-induced mitochondrial superoxide production as analyzed by 
flow cytometry. The cells were treated with different concentrations of SiPcGlu. After 
illumination, the cells were stained with MitoSOX™ Red mitochondrial superoxide 
indicator. The dark controls were cells treated with 12 nM SiPcGlu without illumination. 
The emitted fluorescence due to superoxide production was detected by the PE channel of 
the BD F A C S C a n t o T M flow cytometer. The pattern shown is a representative from three 
independent experiments while the data are Mean 土 S.D. from 3 independent experiments. 
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Figure 3.8 SiPcGlu-PDT-induced mitochondrial superoxide production as analyzed by 
confocal microscopy. The cells were treated with different concentrations of SiPcGlu. After 
illumination, the cells were stained with MitoSOX™ Red mitochondrial superoxide 
indicator. The dark control refers to cells treated with 12 nM SiPcGlu without illumination. 
The emitted fluorescence due to superoxide production was detected by Leica SP5 Confocal 
np* yj 
Laser Scanning Microscope. MitoSOX Red was excited by argon/krypton laser at 514 nm. 
The emitted fluorescence was detected at 580 nm. 
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3.1.6 Glucose competitive Assay 
To better understand the role of glucose moiety in the structure of SiPcGlu, a 
competitive assay was performed. Glucose solutions (1 or 100 mM) were added and 
incubated with different concentrations of SiPcGlu. Twenty-four h after PDT, MTT assay 
was performed to determine whether glucose could inhibit the photocytotoxicity induced by 
SiPcGlu-PDT. Figure 3.9 shows that the cell viability was virtually identical in the presence 
or absence of glucose, which implies that the GLUTS may not be involved in the uptake of 
SiPcGlu. 
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Figure 3.9 Glucose competitive assay. Glucose solutions (1 or 100 mM) were added and 
incubated with different concentrations of SiPcGlu. The 3 groups of treatments included no 
glucose control ( # ) , and cells treated with 100 mM glucose solution ( • ) and 1 mM 
glucose solution (〇 )• The cells were illuminated with halogen lamp (48 J/cm^). Cell 
viability was determined by MTT assay. The data are Mean 土 S.D., n = 4. 
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3.1.7 SiPcGlu-PDT induced apoptosis in HT29 cells 
To study whether SiPcGlu-PDT induces cell death via apoptosis, 24 h after SiPcGlu-
PDT, the cells were subjected to TUNEL, annexin V & propidium iodide staining and DNA 
fragmentation assays. For the TUNEL assay, the DNA breaks of dead cells can be stained 
with fluorescein-2'-deoxyuridine 5'-triphosphate (FITC-dUTP). Figure 3.10 shows that there 
was an obvious increase in the FITC intensity, in a dose-dependent manner (31.4 土 7.26% 
and 89.36 土 6.19o/o in 6 nM and 12nM SiPcGlu-treated cells, respectively). The dark or light 
control cells only showed low FITC intensity (< 2%). To investigate whether the dead cells 
are apoptotic or necrotic cells, DNA laddering assay was performed. A typical DNA ladder 
pattern, a hallmark of apoptosis, was observed at either 24 or 48 h after treating the cells 
with 12nM SiPcGlu-PDT (Figure 3.11). To further differentiate the live, apoptotic and 
necrotic cells in the HT29 cell populations, annexin V & propidium iodide staining assay 
was performed to detect early apoptotic cells which have phosphatidyl serine 
externalization but do not have DNA leakage. The percentage of such cells in the 
population increased in a dose-dependent manner from <10 % for the controls to 27.87 土 
1.91% and 66.58 土 5.92% after treatment with 6 nM and 12 nM SiPcGlu-PDT respectively 
(Figure 3.12). 
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Figure 3.10 SiPcGlu-PDT-induced apoptosis in HT29 cells as analyzed by TUNEL assay. 
The cells were treated with different concentrations of SiPcGlu. Twenty-four h after 
illumination, the cells were treated with the In Situ Cell Death Death Detection Kit, 
Fluorescein. The dark control refers to cells treated with 12 nM SiPcGlu without 
illumination. The emitted fluorescence due to fragmented DNA was detected by the FITC 
channel of the BD FACSCanto™ flow cytometer. The pattern shown is a representative 
from three independent experiments while the data are Mean 土 S.D. from 3 independent 
experiments. 
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Figure 3.11 SiPcGlu-PDT-induced apoptosis in HT29 cells as analyzed by DNA 
laddering assay. The cells were treated with different concentrations of SiPcGlu. Twenty-
four and forty-eight h after illumination, DNA was extracted and analyzed by 
electrophoresis in a 2% agarose gel containing ethidium bromide. 
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Figure 3.12 SiPcGlu-PDT-induced apoptosis in HT29 cells as analyzed by annexin V & 
propidium iodide assay. The cells were treated with different concentrations of SiPcGlu. 
Twenty-four h after illumination, the cells were stained with annexin V & propidium iodide 
solutions. The dark control refers to cells treated with 12 nM SiPcGlu without illumination. 
The emitted fluorescence was detected by the by the PerCP vs FITC channels of the BD 
F A C S C a n t o T M f low cytometer. The percentage of the population of apoptotic cells (LR), 
normal cells (LL) and necrotic cells (UR) are shown. The pattern shown is a representative 
from three independent experiments while the data are Mean 士 S.D. from 3 independent 
experiments. 
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3.1.8 Subcellular localization of SiPcGlu 
Since ROS is only short-lived and has very short migration distance, it is crucial to 
find out the intracellular localization of photosensitizer where it exerts its primary 
photodamage. It was done by co-staining HT29 with SiPcGlu and organelle-specific probes. 
SiPcGlu did not specifically localize in a single organelle. Instead, the confocal overlay 
fluorescence images show that SiPcGlu partially overlapped with different organelle-
specific probes, including those for ER, mitochondria, lysosome and Golgi body (Figures 
3.13 to 3.16). Their line profiles were also drawn and it is shown that SiPcGlu has a partial 
localization in these membranous organelles. 
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Figure 3,13 Subcellular localization of SiPcGlu in HT29 cells (ER), The cells were 
incubated with 0.5 | iM SiPcGlu for 90 min and then ER-Tracker™ Green probe for further 
30 min. The cells were visualized with a Leica SP5 Confocal Laser Scanning Microscope. 
An argon/krypton laser of 488 nm and a helium/neon laser of 633 nm were used. Their 
emitted fluorescences (detected at 516 nm for the ER-Tracker^'^ Green probe and 673 nm 
for SiPcGlu) were captured. (A) The bright field image of HT29 cells. (B) The confocal 
丁\/1 
fluorescence image of SiPcGlu (red) and ER-Tracker Green probe (green). (C) The 
fluorescence line intensity profiles of HT29 cells double-stained with SiPcGlu (dotted line) 
and ER-TrackerTM Green probe (solid line). The line indicates the analyzed longitudinal 
transcellular zone. 
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Figure 3.14 Subcellular localization of SiPcGlu in HT29 cells (mitochondria). The cells 
were incubated with 0.5 | iM SiPcGlu for 90 min and then with MitoTracker Green probe for 
another 30 min. The cells were visualized with a Leica SP5 Confocal Laser Scanning 
Microscope. An argon/krypton laser of 488 nm and a helium/neon laser of 633 nm were 
used. Their emitted fluorescences (detected at 516 run for the MitoTracker Green probe and 
673 nm for SiPcGlu) were captured. (A) The bright field image of HT29 cells. (B) The 
confocal fluorescence image of SiPcGlu (red) and MitoTracker Green probe (green). (C) 
The fluorescence line intensity profiles of HT29 cells double-stained with SiPcGlu (dotted 
line) and MitoTracker Green probe (solid line). The line indicates the analyzed longitudinal 
transcellular zone. 
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Figure 3.15 Subcellular localization of SiPcGlu in HT29 cells (Golgi body). The cells 
were incubated with 0.5 ^iM SiPcGlu for 90 min and then with BODIPY® FL C5-ceramide 
for another 30 min. The cells were visualized with a Leica SP5 Confocal Laser Scanning 
Microscope. An argon/krypton laser of 488 nm and a helium/neon laser of 633 nm were 
used. Their emitted fluorescences (detected at 516 nm for the BODIPY® FL C5-ceramide 
and 673 rnn for SiPcGlu) were captured. (A) The bright field image of HT29 cells. (B) The 
confocal fluorescence image of SiPcGlu (red) and BODIPY® FL C5-ceramide (green). (C) 
The fluorescence line intensity profiles of HT29 cells double-stained with SiPcGlu (dotted 
line) and BODIPY® FL C5-ceramide (solid line). The line indicates the analyzed 
longitudinal transcellular zone. 
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Figure 3.16 Subcellular localization of SiPcGlu in HT29 cells (lysosome). The cells were 
incubated with 0.5 | iM SiPcGlu for 90 min and then with LysoTracker® Green probe for 
another 30 min. The cells were visualized with a Leica SP5 Confocal Laser Scanning 
Microscope. An argon/krypton laser of 488 nm and a helium/neon laser of 633 nm were 
used. Their emitted fluorescences (detected at 516 nm for the LysoTracker® Green probe 
and 673 nm for SiPcGlu) were captured. (A) The bright field image of HT29 cells. (B) The 
confocal fluorescence image of SiPcGlu (red) and LysoTracker® Green probe (green). (C) 
The fluorescence line intensity profiles of HT29 cells double-stained with SiPcGlu (dotted 
line) and LysoTracker® Green probe (solid line). The line indicates the analyzed 
longitudinal transcellular zone. 
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3.1.9 SiPcGlu-PDT induced mitochondrial changes 
Since mitochondria is one of the primary photodamage sites by SiPcGlu-PDT, JC-1 
staining assay was performed to determine whether mitochondrial membrane potential was 
collapsed, which could be indicated by the decrease in ratio of JC-1 red fluorescence to JC-
1 green fluorescence. Figure 3.17 shows that immediately after SiPcGlu-PDT, there was a 
decrease in the red to green fluorescence ratio, which means that immediate collapse of 
mitochondrial membrane potential happened in a dose-dependent manner [12.53 土 2.54o/o 
and 41.96 士 11.88°/0 of HT29 cells had their mitochondrial membranes depolarized after 
treatment with 6 nM and 12 nM SiPcGlu-PDT, respectively when compared with the 
control cells (-5%)]. 
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Figure 3.17 SiPcGlu-PDT-induced mitochondrial membrane depolarization. The cells 
were treated with different concentrations of SiPcGlu. After illumination, the cells were 
stained with JC-1 solution. The dark control refers to cells treated with 12 nM SiPcGlu 
without illumination. The emitted fluorescences were detected by the PE vs FITC channels 
of the BD FACSCanto™ flow cytometer. The percentage of cells with decrease in the red to 
green fluorescence ratio is shown. The pattern shown is a representative from three 
independent experiments while the data are Mean 土 S.D. from 3 independent experiments. 
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3.1.10 SiPcGlu-PDT induced caspase activation 
Release of cytochrome c and the activation of caspases were investigated after 
mitochondrial membrane depolarization. The cytosolic fractions of HT29 cells were 
extracted after treatment with SiPcGlu-PDT. Figure 3.18 shows that there was a significant 
increase in cytochrome c protein level in cytosol of HT29 cells treated with 12nM SiPcGlu-
PDT in a time-dependent manner. Since cytochrome c can trigger the formation of 
apoptosome and activate the caspase cascade, caspase-3 activity assay was performed to see 
whether cleavage of fluorogenic substrate Ac-DEVD-AMC into fluorescent AMC by active 
caspase-3 occurred. Figure 3.19 shows that there is a significant increase in the fluorescence 
intensity after treatment with SiPcGlu-PDT which indicates that active caspase-3 was 
present. Another evidence of caspase-3 activation was illustrated by the Western blot 
analysis. After treatment with 9 nM or 12 nM SiPcGlu-PDT, there was a decrease in the 
protein expression of procaspase-3 while that of active caspase-3 increased (Figure 3.20). 
The activation of caspase-3 in photosensitized cells leads to the cleavage of a number of 
cellular proteins which eventually leads to apoptosis. In the present study, the cleavage of 
PARP, a DNA repair enzyme, was studied. Figure 3.20 shows that after treatment with 9 
nM and 12 nM SiPcGlu-PDT, the protein level of intact PARP was decreased while that of 
cleaved PARP was elevated, which subsequently leads to DNA fragmentation and apoptosis. 
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Figure 3.18 SiPcGlu-PDT-induced release of cytochrome c to cytosol in HT29 cells. The 
cells were treated with different concentrations of SiPcGlu. Four and twenty-four h after 
illumination, the cytosolic fraction of HT29 cells was obtained by the Cytosol/Particulate 
Rapid Separation Kit. SDS-polyacrylamide gel electrophoresis was carried out, followed by 
Western blot analysis. The dark control refers to cells treated with 12 nM SiPcGlu without 
illumination. The pattern shown is a representative from three independent experiments. 
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Figure 3.19 SiPcGlu-PDT-induced caspase-3 activation in HT29 cells (fluorogenic 
substrate). The cells were treated with different concentrations of SiPcGlu. Twenty-four h 
after illumination, the caspase-3 activity was determined by using caspase-3 assay kit. The 
amount of fluorescent product AMC liberated from the substrate Ac-DEVD-AMC by active 
caspase-3 was measured by a spectrofluorometer with excitation and emission wavelengths 
of 380 nm and 440 nm, respectively. The dark control refers to cells treated with 12 nM 
SiPcGlu without illumination, while the inhibitor control refers to cells treated with 12 nM 
SiPcGlu-PDT in the presence of Ac-DEVD-CHO, a synthetic tetrapeptide inhibitor of 
caspase-3 activity.The data represent Mean 土 S.E.M. from three independent experiments, * 
p < 0.05 (Student's t-test) when compared with the light control (0 nM SiPcGlu). 
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Figure 3.20 SiPcGlu-PDT-induced caspase-3 activation in HT29 cells (Western blot 
analysis). The cells were treated with different concentrations of SiPcGlu. Twenty-four h 
after illumination, whole cell lysate of HT29 cells was obtained. SDS-polyacrylamide gel 
electrophoresis was carried out, followed by Western blot analysis. The dark controls were 
cells treated with 12 nM SiPcGlu without illumination. The pattern shown is a 
representative from three independent experiments. 
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3.1.11 SiPcGlu-PDT increased expression of ER chaperone 
GRP78 
Due to the partial localization of SiPcGlu in ER, the involvement of ER in SiPcGlu-
PDT was also investigated. GRP78, an ER stress-induced molecular chaperone, was 
assessed by Western blot analysis at 24 h after SiPcGlu-PDT. For all the SiPcGlu-PDT 
treated cells, there was an abrupt elevation in the GRP78 protein level when compared with 
the control cells (Figure 3.21), which may suggest that ER stress was induced by SiPcGlu-
PDT. 
3.1.12 SiPcGlu-PDT induced release of Ca^ ^ from ER 
As ER is a major Ca^^ store, ER stress may trigger the release of Ca^^ into cytosol 
which may initiate apoptosis. The cytosolic Ca^^ level was investigated using the Fluo-3, A M 
probe. Figure 3.22 shows a dose-dependent increase in Fluo-3 FITC intensity which indicates 
that the cytosolic Ca^^ level increased after treatment with SiPcGlu-PDT. The results may 
suggest that the elevation in cytosolic Ca^^, probably from ER Ca^^ stores, may initiate 
apoptosis in HT29 after SiPcGlu-PDT. 
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Figure 3.21 SiPcGlu-PDT4nduced elevation of GRP78 expression in HT29 cells. The cells 
were treated with different concentrations of SiPcGlu. Twenty-four h after illumination, 
whole cell lysate of HT29 cells were obtained. SDS-polyacrylamide gel electrophoresis was 
carried out, followed by Western blot analysis. The dark control refers to cells treated with 12 
nM SiPcGlu without illumination. The pattern shown is a representative from three 
independent experiments. 
73 
Chapter 3 Results 
OnM§i ^ SnM^j ^ ^ 
5 . 2 0 ± 1 . 7 5 % 1 2 . 6 9 土 2 L 7 6 o/o 
1 丄 J i 
一 。 梟 ， , 。 . m I , 
c 10 Q 101 10 2 10 3 10 4 化1 ib3 
Q FITC-A FITC-A 
^ 1 2 n M g . D a r k 目 
0 , Mi 丨 control r 丨 Mi 丨 
O 4 4 . 7 ± 3 _ 0 4 o / o 6 . 0 6 ± 1 . 8 2 0/0 
I I i 
秦 A 
100 101 102 103 104 100 101 102 103 104 
FITC-A FITC-A 
F l u o - 3 - F I T C 
Figure 3.22 SiPcGlu-PDT-induced release of Ca^^ from ER into cytosol. The cells were 
treated with different concentrations of SiPcGlu. After illumination, the cells were stained 
with Fluo-3, A M probe. The emitted fluorescence due to Ca^^ release from ER was detected 
by the FITC channel of the BD FACSCanto™ flow cytometer. The dark control refers to 
cells treated with 12 nM SiPcGlu without illumination. The pattern shown is a 
representative from three independent experiments while the data are Mean 士 S.D. from 3 
independent experiments. 
74 
Chapter 3 Results 
3.2 In vivo studies 
3.2.1 In vivo photodynamic activities 
To evaluate whether SiPcGlu has the potential to reach clinical studies, animal 
experimentation was done by using a HT29 tumor-bearing nude mice model. Before 
SiPcGlu-PDT, tumor cells were injected subcutaneously into the mice and the volumes of 
the tumor grown at the back of the nude mice were ranged from 51 to 117 mm^ on day 8. 
The tumor volumes of different groups on day 8 were taken as 100%. On day 9, SiPcGlu 
was injected intravenously into the tail vein and laser was spotted onto the tumor after 24 h. 
After SiPcGlu-PDT, for the control groups, the tumor grew normally and reached 4-fold 
increase on day 25. On the contrary, for mice treated with 1 |imole SiPcGlu per kg body 
weight, the tumor growth was significantly retarded on day 13. From then on, the tumor 
volume remained more or less the same and only reached 1.7 fold increase on day 25 
(Figure 3.23). In most cases, oedema of the tumor appeared immediately after irradiation 
and generally disappeared in the following days. Scars were present at 24 h after irradiation 
which normally persisted for about a week and recovered at the end of the experimental 
period. 
75 
Chapter 3 Results 
500 • 
？ 糊 . 
I 300 
u. I l luminat ion ^ 
塞 2 0 0 - I ^ ^ ^ ^ I 
〜。. 
* * 
0 ‘ ‘ ‘ ‘ — 
5 10 15 20 25 
Days after Inoculation 
Figure 3.23 SiPcGlu-PDT-induced tumor growth retardation on the HT29 tumor-bearing 
nude mice. SiPcGlu was intravenously injected into the tail vein of the mice and the tumors 
were illuminated at 24 h with a diode laser (30 J/cm^). The tumor volumes were followed 
for 25 days. The five groups of mice included SiPcGlu-PDT-treated (1 |xmole/kg body 
weight, # ) , dark control (with SiPcGlu, without illumination, •)，light alone control 
(without SiPcGlu, with illumination, • ) , solvent control (with illumination,〇）and no 
treatment control (without SiPcGlu and illumination, • ) . The data are Mean 士 S.E.M. (n = 
6 for each group of mice). * < 0.05 (One-way ANOVA with Holm-Sidak method) when 
the PDT-treated group was compared with all the four control groups, 
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3.2.2 Biodistribution of SiPcGlu 
In the hope that the glucose moieties of SiPcGlu may promote photosensitizer 
uptake by the tumor through the GLUTS, which are over-expressed in tumor cells, 
biodistribution study of SiPcGlu was performed in the tumor-bearing nude mice. The 
greatest retention of SiPcGlu was found in skin, kidney and tissues of the reticulo-
endothelial system, viz. liver and spleen. For muscle and lung, there was only a relatively 
small portion of SiPcGlu accumulated, which was similar to the pharmacokinetic profile of 
tumor (Figure 3.24). 
3.2.3 Analysis of intrinsic toxicity 
In order to evaluate the safety use of SiPcGlu for clinical application, a preliminary 
intrinsic toxicity analysis of SiPcGlu, particularly in liver, was evaluated. ALT and AST 
were used to evaluate whether hepatic injury was induced. The increase in their plasma 
levels wi l l suggest the presence of liver damage. CK was also used to evaluate whether 
cardiac injury was induced and any increase in its level suggests the presence of heart 
damage. The plasma of nude mice was obtained 15 days after PDT. The enzyme activities 
of ALT, AST and CK of plasma were evaluated and their levels in SiPcGlu-PDT treated 
mice were similar to all the control groups (Figure 3.25), suggesting that there was no 
significant acute hepatic or cardiac injuries induced by SiPcGlu. 
77 
Chapter 3 Results 
4 - T 
o 
3 
^ n T T 
o T 





e 1 - i r - 1 
ss n 门 
Figure 3.24 Tissue distribution of SiPcGlu in HT29 tumor-bearing nude mice. SiPcGlu was 
injected intravenously into the tail vein of the HT29 tumor-bearing nude mice. After 24 h, 
different organs/tissues were excised and homogenized with DMF. The peak fluorescence 
intensity of the extract was recorded by scanning the fluorescence emission spectrum from 
610 nm to 900 nm using an excitation wavelength at 608 nm with a spectrofluorometer. 
Amount of SiPcGlu present in the sample was determined with reference to the standard 
curves of different organs/tissues. % ID per gram of tissue was calculated. Data are the Mean 
土 S.E.M., n = 6. 
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Figure 3.25 Plasma enzyme activity assay. Plasma samples were obtained by cardiac 
puncture of mice at 15 days after SiPcGlu-PDT. The five groups of mice included SiPcGlu-
PDT-treated (1 |imole/kg body weight), dark control, light control, solvent control and no 
treatment control. The ALT, AST and CK activities were determined by using commercially 
available enzyme assay kits. Data represent Mean 土 S.E.M., n = 6. 
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Chapter 4 Discussion 
In recent years, PDT has emerged as a promising therapy for treatment of malignant 
and non-malignant diseases. Due to the drawbacks of the most commonly prescribed 
photosensitizer Photofrin®, ongoing research has been conducted to develop potential 
photosensitizers for cancer treatment. In our laboratory we have synthesized a number of 
glycosylated silicon(IV) and zinc(II) phthalocyanines (Choi et al., 2008; Liu et al., 2009; Lo 
et al., 2008). Most of them possess desirable physical properties and potent photodynamic 
activities. Among them the SiPcGlu is the most potent one (Figure 1.7， IC50 is 6 nM 
against HT29 and HepG2) (Lo et al., 2007). To further investigate whether SiPcGlu has the 
potential for clinical applications in cancer treatment, both in vitro and in vivo studies were 
performed. 
4.1 Physical Properties of SiPcGlu 
Conjugating photosensitizers with saccharides such as glucose and galactose can 
prevent their aggregation, increase water solubility and biological efficacy (Maillard et al., 
1989). Our laboratory has previously described the preparation of silicon(IV) 
phthalocyanine conjugated to galactose via axial coordination and found that these 
compounds are highly soluble in most organic solvents and remain essentially non-
aggregated in solution. Moreover, these compounds show an improvement in cellular 
uptake and enhanced photocytotoxicities against HepG2 (Lee et al., 2005). We have 
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employed glucose as an axial ligand to silicon(IV) phthalocyanine. It was hoped that this 
biocompatible moiety can enhance water solubility, minimize self-aggregation and thus 
potentiate photocytotoxicity of silicon(IV) phthalocyanine. SiPcGlu is soluble in organic 
solvents and exhibits substantial solubility in water. It is noteworthy that the original 
silicon(IV) phthalocyanine is completely insoluble in water and even in many organic 
solvents, therefore the protected glucose can greatly enhance the hydrophilicity of SiPcGlu 
and also the uptake of drug into the cells, which may explain its high photocytotoxicity 
against both HepG2 and HT29 cells. Moreover, the electronic absorption spectra of SiPcGlu 
in DMF or culture medium show an intense and sharp Q-band at 673 nm (Lo et al., 2007). 
This strong absorption peak in the far-red region of the visible spectra can ensure deeper 
penetration of light into the skin and thus trigger photoreaction more efficiently (Lane, 
2003). 
4.2 In vitro studies 
4.2.1 SiPcGlu-PDT exhibits a high potency in killing HT29 cells 
SiPcGlu is highly potent against HT29 with the IC50 and IC90 values down to 6 (7.8 
ng/ml) and 12 nM respectively under the illumination of halogen lamp of 48 J/cm^ (Lo et al., 
2007). To compare the photocytotoxicity with the commonly prescribed photosensitizer 
Photofrin®, the same experimental setup was used and the IC50 of Photofrin⑧ in killing 
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HT29 was ~5 |ig/ml’ which is much less potent than SiPcGlu. The cytotoxicity of SiPcGlu 
without irradiation was investigated to determine whether it is essentially non-toxic in 
darkness. Results of MTT assay reveals that SiPcGlu alone do not produce any cytotoxicity 
(Figures 3.1 and 3.2). 
The absorption peak of SiPcGlu is 673 nm (Lo et al., 2007). For the light source that 
we used (Halogen lamp, X > 610 nm), only a narrow region of the light (at ca. 610-700) was 
absorbed by SiPcGlu to initiate the photodynamic action. Therefore the total energy 
required to produce the cytotoxicity effect should be much lower. In order to study the 
actual amount of light dose required for SiPcGlu-PDT, the cells were illuminated with a 
monochromatic diode laser which can generate light with wavelength (675 土 3 nm) very 
close to the excitation maxima of SiPcGlu. Figure 3.3 shows that a total fluence of 8 J/cm^ 
(power = 0.2 W, time = 40 s) is sufficient to attain a similar effect. 
4.2.2 ROS production is responsible for the cytotoxicity effect of 
SiPcGlu 
It is well-known that ROS generated by PDT via Type I or Type I I photoreaction is 
the main cause of cell death. In both reactions, different types of ROS are produced. 
Superoxides, hydroperoxyl, radicals and peroxides are formed in Type I photoreaction 
while singlet oxygen (the most damaging ROS) are formed in Type I I photoreaction 
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(Calzavara-Pinton et al., 2007; Triesscheijn et al., 2006). In order to study the action 
mechanism of SiPcGlu-PDT, we have employed the fluorescent probe DCFDA to 
investigate whether ROS was produced during PDT. DCFDA can only be deacetylated by 
intracellular esterase to 2' ,7'-dichlorofluorescein (DCF) which is then oxidized by ROS to 
give the characteristic fluorescence. Figure 3.4 shows that photodynamic treatment with 
SiPcGlu induced a dose-dependent increase in ROS production. Therefore, it is believed 
that ROS is produced during SiPcGlu-PDT. To elucidate whether ROS is the cause of cell 
death by SiPcGlu-PDT, the cell survival and ROS production curves were compared. The 
dose-dependent curve for the survival of HT29 correlates well with the ROS production 
curve. Hence it is believed that the photodynamic treatment results in the production of 
ROS which then triggers the process to cell death. 
Type I and Type II photoreactions can occur simultaneously, and the ratio between 
these two processes depends on the sensitizer, substrate and oxygen concentration (Jakus et 
al., 2005). It has been generally accepted that the Type I I reaction predominates in 
oxygenated systems while the Type I reaction prevails under hypoxic conditions (Baumler 
et al., 1999; Chan and Wu, 2004; Ding et al., 2004). In order to investigate whether Type I 
or Type I I photoreactions are the predominant mechanism of action, a quencher of hydroxyl 
radical, D-mannitol and quenchers of singlet oxygen, L-histidine or vitamin C were used. 
Chan and Wu (2004) reported that the apoptotic effects caused by Rose Bengal-PDT can be 
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blocked by singlet oxygen scavangers L-histidine and a-tocopherol, but not by hydroxyl 
radical scavenger D-mannitol, indicating that singlet oxygen (Type II photoreaction) is 
responsible for photocytotoxicity. On the other hand, Ding et al. (2004) reported that the 
singlet oxygen quencher sodium azide or the hydroxyl radical scavenger D-mannitol could 
protect HeLa cells from apoptosis and necrosis induced by hematoporphyrin monomethyl 
ether (HMME)-PDT, showing that hydroxyl radical (Type I photoreaction) and singlet 
oxygen (Type I I photoreaction) play a decisive role in HMME-PDT-induced HeLa cells 
death. Figure 3.5 shows that both the hydroxyl radical scavenger D-mannitol, and the 
singlet oxygen quenchers L-histidine and vitamin C could slightly inhibit the HT29 cells 
from photodamage by SiPcGlu-PDT. These results suggest that ROS initiates cell death of 
HT29 and it is believed that both hydroxyl radical and singlet oxygen are involved, via 
Type I and Type I I photoreactions. 
4.2.3 SiPcGlu-PDT induced apoptosis in HT29 cells 
Apoptosis is an ATP-requiring process which is morphologically characterized by 
cell shrinkage, plasma membrane blebbing, formation of apoptotic bodies with membrane 
integrity and cleavage of chromosomal DNA into internucleosomal fragments. In vivo, the 
apoptotic bodies are scavenged by phagocytes, inflammation is prevented and cells die 
under "immunological control" (Buytaert et al., 2007). At the biochemical level, apoptosis 
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may recruit the activation of caspases which are endopeptidases that employ cysteine at the 
active site and cleave their targets at aspartic acid residues (Leist and Jaattela, 2001). Al l 
caspases are synthesized as proenzymes or zymogens and are activated in response to the 
apoptotic signals by proximity-induced dimerization at a multimeric protein complex 
(initiator caspases) or by limited proteolysis by upstream caspases (effector caspases) 
(Boatright and Salvesen, 2003; Luthi and Martin, 2007). Proteolytic cleavage of cellular 
substrates by the effector caspases determines the features of apoptotic cell death. 
After SiPcGlu-PDT, HT29 cells underwent apoptosis as evidenced by three assays. 
The first evidence is the presence of TUNEL positive cells. After PDT, the cells were 
incubated with the TUNEL reaction mixture containing terminal deoxynucleotidyl 
transferase (TdT) and FITC-dUTP. TdT can catalyze the attachment of FITC-dUTP to free 
3,OH ends of the DNA breaks in dead cells. Figure 3.10 shows that upon SiPcGlu-PDT, 
there was an elevation of FITC fluorescence intensity due to increase in the number of 
TUNEL-positive cells. However DNA breaks caused by necrosis can also be stained by 
TUNEL assay. To avoid ambiguity, DNA fragmentation, a hallmark of apoptosis, was 
studied by gel electrophoretic analysis. DNA ladder pattern shown in Figure 3.11 clearly 
reveals the presence of nucleosomal DNA fragmentation after SiPcGlu-PDT. Another 
hallmark of apoptosis is the externalization of phosphotidylserine into the leaflet of the 
plasma membrane with no DNA leakage, which can be observed by simultaneous staining 
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of annexin V & propidium iodide. The flow cytometric analysis of both fluorescence signals 
indicates that the cells undergo apoptosis after SiPcGlu-PDT, as evidenced by the increase 
in cell populations having annexin V binding and no significant change in propidium iodide 
staining (Figure 3.12). 
4.2.4 SiPcGlu is localized in various membranous organelles 
The subcellular localization of the photosensitizers is of special importance, since it 
determines the primary site of photodamage which triggers different types of cell death. 
Singlet oxygen is very short-lived and can only damage biomolecules in their close 
proximity. The cellular structures having both a high photosensitizer and a high oxygen 
concentration wi l l preferentially be damaged. The important structural features of 
photosensitizers are (a) the net ionic charge, (b) the degree of hydrophobicity expressed as 
the logarithm of the octanol/water partition coefficient, (c) the degree of asymmetry present 
in the molecule. Different structural features of photosensitizers wi l l lead to different 
subcellular localization. Many hydrophobic photosensitizers localize in mitochondria or 
membranous organelles and exert their primary damage there (Moor, 2000). They can be 
specifically localized in one organelle or non-specifically in several organelles. Our 
previous study has shown that the unsymmetrical BAM-SiPc is localized in the 
mitochondria specifically (Lo et al., 2004). Noodt et al. (1999) reported that the 
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hydrophobic tetra(3-hydroxyphenyl)porphyrin (3THPP) is localized in intracellular 
membranes of Chinese hamster lung fibroblasts (V79) cells. Silicon phthalocyanine also 
exhibits a preferential localization in mitochondria, Golgi body and endoplasmic reticulum 
of epidermoid carcinoma (A431) cells (Lam et al., 2001). These mitochondria-localized 
photosensitizers can trigger cell death via apoptosis after photoactivation. On the other hand, 
photosensitizers which are hydrophilic in nature tend to localize in lysosome by endocytosis 
or distributed homogenously throughout the cytoplasm and nucleoplasm. One example of 
hydrophilic photosensitizer is tetraphenylporphyrin which can be taken up into lysosomes 
by endocytosis in V79 cells (Noodt et al., 1993). Lysosome-localized photosensitizers can 
trigger cell death via necrosis or apoptosis. Photosensitizers can also be localized on the 
plasma membrane. Hsieh et al. (2003) revealed that plasma membrane of A431 cells are the 
primary targets of Photofrin® which can cause cell death via necrosis upon photoactivation. 
Recent study has hypothesized that the similarity in structures of photosensitizers and 
cellular structures could promote the formation of preferred molecular complex. Ho et al. 
(2009) reported that hypericin and cholesterol molecules, which share common molecular 
morphology of rigid planar configuration, provided the driving force for the lipid-mediated 
preferential localization of hypericin in lipid membranes. 
Confocal laser scanning fluorescence microscopy is usually used for the 
determination of intracellular localization of photosensitizers. Co-staining of subcellular 
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organelle-specific probes with photosensitizers of different fluorescence emission maxima 
can be used to identify the site of localization. In this study, confocal microscopic 
investigation of SiPcGlu，s intracellular localization was done by co-staining with 
MitoTracker® Green FM, ER-Tracker™ Green, BODIPY® FL C5-ceramide or 
LysoTracker® Green Probes. The confocal images show that all the organelle-specific 
probes had a partial overlap with SiPcGlu. The fluorescence line profile also reveals that all 
the organelle-specific probes had similar fluorescence profiles to that of SiPcGlu, indicating 
that SiPcGlu localizes different intracellular organelles (Figures 3.13 to 3.16). Therefore 
SiPcGlu-PDT can exert its photodamage effect in different cellular compartments. The 
hydrophobic silicon(IV) phthalocyanine exhibits a preferential localization in mitochondria, 
Golgi body and ER (Lam et al., 2001). Since SiPcGlu is axially conjugated with two 
glucose moiety in a symmetric manner, its hydrophilicity increases which may cause its 
localization in lysosomes as well. 
4.2.5 SiPcGlu-PDT induced mitochondrial-mediated apoptosis 
ROS production after SiPcGlu-PDT was also found in HT29 cells (Figure 3.6). Such 
increase may be due to the damage of mitochondrial respiratory chain caused by SiPcGlu-
PDT and may result in higher oxygen tension (Varnes et al., 1999). This phenomenon was 
termed by Zorov et al. (2000) as "ROS-induced ROS release". It was found that after 
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photodynamic treatment with tetramethylrhodamine derivatives, the ROS production during 
PDT caused abrupt mitochondrial depolarization and a burst of mitochondrial ROS 
generation. The mechanisms of the ROS burst is believed to be due to the damage of 
mitochondrial respiratory chain, especially mitochondrial Complexes I and I I I which are the 
major sources of ROS. The induction of mitochondrial membrane depolarization can affect 
the proper function of these respiratory chains. Photodamage to these sites can cause ROS 
burst (Zorov et al., 2000). 
In this study, it was found that SiPcGlu was partially localized in mitochondria, 
investigations were done to see whether SiPcGlu-PDT could affect the mitochondrial 
membrane depolarization by JC-1 staining. JC-1 exhibits potential-dependent accumulation 
in mitochondria, indicated by a fluorescence emission shift from green to red. When 
mitochondrial depolarization occurs, the red/green fluorescence intensity ratio wi l l be 
decreased. Figure 3.17 shows that immediately after SiPcGlu-PDT, there was an increase in 
cell populations having red/green fluorescence ratio decreased, suggesting that HT29 cells 
undergo mitochondrial membrane depolarization after SiPcGlu-PDT. 
We speculated that ROS insults to mitochondria by SiPcGlu-PDT may also induce 
ROS production by mitochondria to trigger apoptosis. MitoSOX™ Red mitochondrial 
superoxide indicator was developed for selective detection of superoxide in the 
mitochondria of live cells. SiPcGlu-PDT caused immediate generation of ROS from 
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mitochondria in a dose-dependent manner, as demonstrated by the flow cytometric analysis 
of MitoSOX™ Red at 30 min post irradiation (Figure 3.7). In addition, the confocal 
microscopic imaging reveals that there was a significant increase in mitochondrial 
丁 K/1 
fluorescence intensity of MitoSOX'^' Red after PDT (Figure 3.8), demonstrating that 
SiPcGlu-PDT induces mitochondrial ROS production. However, it is noteworthy that 
nuclear and cytosolic staining by MitoSOX™ Red could also be observed. The reason for 
nuclear staining is that MitoSOX™ Red can bind to DNA following oxidation while 
cytosolic staining may be due to the oxidation of MitoSOX™ Red during its transport from 
cell membrane to mitochondria. However, this level of cytosolic oxidized MitoSOX™ Red 
is much less when compared with the fluorescence detected in mitochondria 
(Mukhopadhyay et al., 2007) 
Many hydrophobic photosensitizers are localized in mitochondria and elicit rapid 
mitochondria-mediated apoptosis after PDT. Moreover, for photosensitizers which localize 
in other intracellular organelles such as endoplasmic reticulum, lysosomes or Golgi body, 
photodamage may also be propagated to mitochondria by various means. Foscan®, a 
photosensitizer localized in ER and Golgi body, can result in mitochondrial depolarization 
and cytochrome c release in a fluence-dependent manner, after its photosensitization in 
human breast adenocarcinoma (MCF-7) cells (Teiten et al., 2003). Previous study has also 
reported that a lysosomal photosensitizer N-aspartyl chlorin e6 (NPe6) caused 
91 
Chapter 4 Discussion 
mitochondrial membrane depolarization, cytochrome c release and triggered mitochondria-
mediated apoptosis, through the release of lysosomal protease and Bid activation to trigger 
the mitochondrial alternations (Reiners et al., 2002). 
Primary photodynamic damage by SiPcGlu-PDT to mitochondria causes immediate 
opening of the permeability transition pore complex and release of cytochrome c into the 
cytosol (Figure 3.18), which is the hallmark of mitochondria-mediated apoptosis. It is well-
known that in the cytosol, cytochrome c can bind to apoptotic protease activating factor 1 
(Apaf-1) and in the presence of dATP or ATP, Apaf-1 adopts a conformation to enhance its 
ability to associate with procaspase-9, which promotes the cleavage of procaspase-9 into 
active caspase-9 to cleave and activate procaspase-3 (Nunez et a l , 1998; Porter and Janicke, 
1999). Caspase-3 is a key player in executing apoptosis. It cleaves a number of proteins 
which are involved in cell structure and maintenance including DNA fragmentation factor 
and PARP. PARP is a DNA repair enzyme which acts by transferring ADP-ribose polymers 
to histones and other nuclear proteins. The cleavage of PARP wi l l disrupt its function and 
may unleash endonuclease activity within dying cells and promote DNA fragmentation 
(Nicholson et a l , 1995). In PDT, the cleavage of PARP has largely been documented. The 
photoactivated hypericin can induce cleavage of PARP under apoptotic conditions in 
cervical carcinoma (HeLa) cells (Vantieghem et a l , 1998). For photodynamic treatment 
with the photosensitizer benzoporphyrin derivative monoacid ring A, activation of caspase-
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3 and 6, as well as the cleavage of PARP were also found (Granville et al., 1999). In this 
study, it was found that the release of cytochrome c after SiPcGlu-PDT leads to the 
activation of caspase-3 and the cleavage of PARP, which results in DNA fragmentation 
(Figures 3.19 and 3.20). 
4.2.6 SiPcGlu-PDT induced ER stress 
Since SiPcGlu also localizes partially in ER, further studies were done to investigate 
the role of ER in triggering apoptosis by SiPcGlu-PDT. ER is the first compartment in an 
ordered membranous network called secretory pathway, which is responsible for the 
synthesis, modification and delivery of biologically active proteins to their proper target 
sites within the cells and the extracellular milieu, as well as regulation of intracellular Ca^^ 
levels. ER is important for the proper folding of protein. I f the amount of unfolded 
polypeptides exceeds the folding and processing capacity of the ER, the normal 
physiological state of the ER is perturbed and this wi l l cause ER stress. Under these 
conditions, unfolded protein response (UPR) is activated. UPR can increase the folding 
capacity of the ER through induction of ER-resident molecular chaperones and foldases, or 
downregulate the biosynthetic load of the ER through shut-off of protein synthesis at both 
transcriptional and translational levels. However, when these mechanisms do not remedy 
the excessive stress, apoptosis is initiated in higher eukaryotic organisms to eliminate 
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unhealthy or infected cells. (Mattson et al., 2000; Schroder and Kaufman, 2005; Sherman 
and Goldberg, 2001). During PDT, oxidative damage to ER can result in dramatic changes 
in ER homeostasis, which proceeds through disruption of Ca^^ homeostasis and 
accumulation of misfolded proteins (Buytaert et al., 2006; Kessel et al., 2005; Mak et al., 
2004). Marchal et al. (2007) had reported that photoactivation by the ER-localized 
photosensitizer Foscan® in MCF-7 cells exhibited upregulation of GRP78 protein, which is 
a chaperone protein known to be induced by the UPR, thus assuming a classic ER oxidative 
stress response following PDT. Since SiPcGlu also localizes in ER, it is believed that 
SiPcGlu-PDT can also induce oxidative stress to ER. We studied the protein expression of 
GRP78 and its elevation may suggest that a classic ER stress response can be induced 
following SiPcGlu-PDT (Figure 3.21). 
The role of ER in triggering apoptosis by SiPcGlu-PDT was also studied. ER is a 
major Ca^^ store. Induction of the molecular chaperones helps to control intracellular Ca^^ 
homeostasis (Mak et al., 2004). A possible reason for the depletion of Ca^^ from ER stores 
2+ 
may be related to sarco/endoplasmic reticulum Ca ATPase (SERCA2) degradation. 
SERCA2 is located on the ER membrane and pumps cytosolic Ca^^ into ER to maintain 
Ca2+ homeostasis within the cells. SERCA2 is highly sensitive to PDT which eventually 
leads to release of Ca^^ from ER. Previous studies have shown that both the hypericin and 
verteporfin-mediated PDT could immediately cause photodamage of SERCA2 pump and 94 
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deplete ER-Ca stores into cytosol, committing cells to death (Buytaert et al., 2006; 
Granville et al., 2001). Endonucleases in many model systems were found to be dependent 
on Ca2+ for internucleosomal cleavage of DNA. Therefore, it was suggested that increased 
Ca2+ may be necessary to allow nuclease activity. Other types of Ca^^-dependent enzymes 
such as the neutral protease calpains are also implicated in apoptosis, which can activate 
subsequent caspase cascade and trigger apoptosis (Nakagawa and Yuan, 2000; Tan et al., 
2006). The role of Ca^^ in triggering apoptosis was also previously studied by the use of an 
ER stress reagent. The Ca^^-ATPase inhibitor thapsigargin, which depleted intracellular 
Ca2+ stores, induced large increase in cytosolic Ca^^ concentration and caused apoptosis in 
mouse T lymphoma (S49) cells (Bian et al., 1997). To study whether Ca^^ is released from 
ER to cytosol, Fluo-3 Ca^^ indicator was used. Upon binding to Ca^^, Fluo-3 wi l l exhibit 
large increase in fluorescence intensity. By analyzing the fluorescence intensity with flow 
cytometry, the cytosolic Ca^^ level in HT29 cells can be determined. Figure 3.22 shows that 
there is a dose-dependent increase in the Fluo-3 FITC intensity, which implies that there 
was an increase in the cytosolic Ca^^ level. This result indicates that the elevation of 
cytosolic Ca2+, probably from ER Ca^^ stores, may initiate apoptosis in HT29 after SiPcGlu-
PDT. 
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4.3 In vivo studies 
4.3.1 SiPcGlu failed to target to tumor tissues 
In the in vitro study we have shown that SiPcGlu exhibits excellent phototoxicity 
towards HT29 cancer cell lines. The development of new photosensitizer for PDT is 
complex, and multi-step preclinical experimental tests are required. Animal experimentation 
is the second chronological step in preclinical investigation (Longo et al., 2009). To 
evaluate whether SiPcGlu has the potential to reach clinical study, we investigated the in 
vivo efficacy of SiPcGlu-PDT by using HT29 tumor-bearing nude mice. One limitation of 
the conventional PDT approach for cancer treatment is the lack of selectivity towards tumor 
tissues. Unfortunately the majority of the photosensitizers are taken up non-selectively by 
all cell types and consequently they can accumulate in tumor and also in normal cells. There 
is a need for increased selectivity of photosensitizer for tumor tissue over healthy tissue; 
without this specificity, PDT has limited clinical applications (Josefsen and Boyle, 2008b). 
Therefore, in order for PDT to reach its full potential, there is a need for various 
photosensitizers and numerous targeting motifs so that all cell and tissue types can be 
selectively destroyed. 
Several approaches were used to increase photosensitizer's selectivity to tumor 
tissues. One approach is to conjugate a targeting component such as antibody which can be 
directed against the tumor antigens or conjugate an antigen which can target the receptor-
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binding sites on the tumor cells. In addition, molecular carriers such as liposome or targeted 
nanoparticles are also being extensively used in cancer therapy because they can enhance in 
vivo drug solubility by incorporating water-insoluble photosensitizers into their 
hydrophobic cores (Lassalle et al., 2009; Lee et al., 2009). Nanoscale polymeric carrier-
encapsulated photosensitizer has prolonged circulation time, allowing them to accumulate 
in tumor tissue and avoiding the reticuloendothelial system. In recent years, a variety of 
carbohydrate-conjugated photosensitizers have been synthesized and evaluated for PDT 
efficacy (Pandey et a l , 2007). One of the biochemical hallmarks of malignancy is enhanced 
tumor glycolysis, which is primarily due to the overexpression of GLUTS and increased 
activity of the mitochondrial-bound hexokinase. Various groups have studied the specificity 
of photosensitizer-saccharide conjugates in different cell lines. Fujimoto et al. (2002) have 
shown that galactoconjugated-tetraphenyl porphyrins but not glycoconjugated- tetraphenyl 
porphyrins showed specificity for rat hepatoma RLC-16 cells which have receptors for 
asialoglycoproteins. Chen et al. (2004) have demonstrated higher specificity and selectivity 
of a tetraglucose conjugate of tetra(pentafluorophenyl)porphyrin linked by a sulfur atom 
towards human breast cancer cells, when compared with the corresponding tetra-galactose 
conjugate. Pyropheophorbide 2-deoxyglucosamide is an example of incorporating 2 
deoxyglucosamine moiety to a photosensitizer and was found to be selectively accumulated 
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inside the tumor compared to surrounding normal tissue, via the GLUT/hexokinase pathway. 
This selectivity could be competitively inhibited by 50 mM D-glucose (Zhang et al., 2003). 
In our study, the strategy used to increase tumor selectivity is to conjugate glucose 
moiety to the photosensitizer. Glycoconjugation can modify the amphiphilicity of 
macrocycles and favor their interaction with the surface membrane of the tumor cells. The 
physical properties of SiPcGlu indicated that the glucose moiety can enhance the 
hydrophilicity of this compound. We hope that the protected glucose moieties of SiPcGlu 
may promote photosensitizer uptake by the tumor through the over-expressed GLUTS. Thus 
in vitro glucose competitive assay and in vivo biodistribution study were performed. In the 
in vitro glucose competitive assay, since D-glucose (25 mM) is present in the culture media, 
PBS was used to formulate the SiPcGlu and glucose solutions. The cytotoxicity was 
determined by MTT assay (Figure 3.9). The cell survival curves in the presence and absence 
of glucose are virtually identical and this result suggests that GLUT may not be involved in 
the uptake of SiPcGlu. To further verify whether the glucose moiety can enhance the uptake 
of SiPcGlu into the tumor, SiPcGlu was injected intravenouesly into the tail vein of the 
mice and its biodistributions in different organs /tissues were evaluated. SiPcGlu retained in 
different organs/tissues was extracted by homogenizing the tissues with DMF and 
quantified by spectrofluorometer excited at 673 nm, which is the absorption maximum 
wavelength of SiPcGlu. A significant accumulation of SiPcGlu was observed in various 
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organs such as lungs, muscle, spleen, skin, kidneys and especially liver, which exhibited the 
highest accumulation of SiPcGlu. Though SiPcGlu failed to specifically target to tumor 
tissues, a significant amount was found in tumor (Figure 3.24) which may be sufficient to 
inhibit tumor growth. Meanwhile, intrinsic toxicities analyses were done to investigate 
whether its highest accumulation in liver may pose hepatic damage to the nude mice. 
4.3.2 SiPcGlu-PDT induced retardation in tumor growth 
The efficacy of a photosensitizer depends on many critical parameters which include 
the molar absorption coefficient of the compound at the therapeutic window. It has been 
shown that wavelengths above 600 nm provide a more effective light penetration into the 
tissue since absorption and scattering of light by human tissue is less extensive in these 
circumstances (Delaey et al., 2003). SiPcGlu has a maximum absorption peak at 673 nm. In 
the in vivo study of SiPcGlu-PDT, we injected SiPcGlu into the tail vein of the nude mice 
and administered a single dose of irradiation at 24 h, which was delivered by an optic fiber 
onto the tumor. Four controls were done, namely (1) solvent control with irradiation, (2) 
light control, (3) SiPcGlu dark control and (4) no treatment control. The light source used in 
this study was a monochromatic laser, with a total fluence of 30 J/cm^. With the use of an 
optic fibre, only a small area (〜1 cm，）could be illuminated, so that the illumination of 
healthy tissues could be minimized. 
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In the SiPcGlu-PDT treated groups, oedema of tumors appeared immediately after 
PDT, followed by significant inhibition of tumor growth in the following weeks when 
compared with the 4 control groups. The tumor volume only increased by 1.7 fold, which 
was significantly lower when compared with the control groups (4-fold increase). SiPcGlu 
alone, solvent with irradiation or light alone did not exert any cytotoxicity to the tumor cells. 
Inhibition in tumor growth was resulted when a combination of drug and light were applied 
onto the tumor (Figure 3.23). Direct photodamage can cause reduction in the number of 
clonogenic tumor cells. In our study, complete tumor eradication cannot be accomplished. 
The result is in accordance with the findings of other groups working on the HT29 tumor 
model. For example, tumor eradication cannot be fully achieved with the treatment of 30 
mg/kg Photofrin® or 5 mg/kg diphenylchlorin photosensitizer of body weight (Bourre et al., 
2003; Hajri et al., 2002). This observation could be attributed to the non-homogenous 
distribution of photosensitizer within the tumor or oxygen depletion since rapid and 
substantial reduction in the tissue oxygen tension appears during PDT (Chin et al., 2004; 
Dolmans et al., 2003). In addition, efficacy of PDT is limited by penetration of light into 
tissue (5-8 mm). Therefore the tumor beyond the penetration distance cannot be destroyed. 
It was believed that the presence of the remnant viable and uninjured tumor cells at their 
base was responsible for the delayed reappearance of tumor growth in PDT-treated mice 
(Hajri et al., 2002). However, in terms of therapeutic efficacy, it is believed that SiPcGlu is 
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a more potent one, in terms of photosensitizer and light dose, when compared with the 
commonly prescribed photosensitizers. 
4.3.3 SiPcGlu is a safe photosensitizer for clinical PDT 
Though SiPcGlu is a potent photosensitizer in inhibiting tumor growth, its high 
accumulation in liver is a major concern of safety in use. Therefore, whether SiPcGlu-PDT 
can cause intrinsic toxicity to the animal should be addressed before any clinical application. 
In this study, some preliminary intrinsic toxicity analyses were performed, especially those 
concerning hepatic injury due to its high accumulation in liver. It has been reported that 
hepatic injury was resulted with high dosage treatment of ZnPcP2S2 on Wistar rat (Zhang et 
a l , 2006). Hepatic injury on Syrian golden hamster was also found when treated with 
verteporfm combined with high light dose (Ayaru et al., 2007). Plasma determinations were 
adopted to evaluate the levels of aspartate aminotransferase and alanine aminotransferase 
(AST and ALT), which are the biochemical markers of hepatic injury, as well as creatine 
kinase (CK), which is the biochemical marker of cardiac injury. These enzymes are 
predominantly present inside the cells. When hepatic or cardiac injuries are present, the 
levels of these enzymes in plasma wi l l be elevated. After SiPcGlu-PDT, plasma of nude 
mice was obtained by intra-cardiac puncture and used for the enzyme activity assays. Figure 
3.25 shows that the plasma levels of AST, ALT and CK were basically the same for the 
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different groups of mice, suggesting that the treatment does not cause any major hepatic and 
cardiac injuries to the nude mice. This preliminary toxicity test shows that SiPcGlu is a safe 
photosensitizer for clinical applications. 
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Chapter 5 Conclusion and Future Perspectives 
5.1 Conclusion 
SiPcGlu exhibits excellent physical properties as a photosensitizer, including its 
good water solubility, minimal self-aggregation and absorption maximum at 673 nm. In this 
study we have further evaluated the in vitro and in vivo efficacy of SiPcGlu-PDT in killing 
HT29 human colorectal adenocarcinoma. In the in vitro cytotoxicity assay we have shown 
that SiPcGlu is highly cytotoxic to HT29 in a dose-dependent manner with IC50 and IC90 as 
low as 6 nM and 20 nM respectively. In vivo tumor regression study has also revealed that 
SiPcGlu is effective in inhibiting tumor growth in the HT29 tumor-bearing nude mice 
model, as compared with the most conventionally prescribed photosensitizer Photofrin®. 
This compound does not cause toxicity in darkness, both in vitro and in vivo. We have also 
shown that its cytotoxic effects may be attributed to the production of ROS, as 
demonstrated by the correlation of cell survival and ROS production. Both hydroxyl radical 
and singlet oxygen may be involved in killing HT29 by SiPcGlu-PDT. 
Similar to the action mechanism of most photosensitizers, the increased ROS 
production in SiPcGlu-PDT-treated cells leads to cell death via the apoptotic pathway, as 
evidenced by the presence of TUNEL positive cells, DNA ladder electrophoretic pattern 
and externalization of PS with no significant DNA leakage. 
Subcellular localization studies show that SiPcGlu can be found in mitochondria, ER, 
Golgi body and lysosomes. It was found that both mitochondria and ER participate in 
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triggering apoptosis. A classical mitochondrial intrinsic pathway is triggered by SiPcGlu-
PDT. SiPcGlu-PDT can cause immediate production of mitochondrial ROS and collapse of 
mitochondrial potential, followed by release of cytochrome c and caspase-3 activation to 
cleave PARP and result in DNA fragmentation. SiPcGlu-PDT can also cause ER oxidative 
stress response in HT29, as evidenced by the elevation of ER chaperone protein and the 
depletion of Ca^ "^  from ER store. 
Although the glucose moiety of SiPcGlu is not able to target the photosensitizer to 
tumor tissue in HT29-tumor-bearing nude mice, this drug is potent enough in inhibiting 
tumor growth in nude mice. Despite the high accumulation of SiPcGlu in liver, the plasma 
enzyme activity assays of AST and ALT at the end of the experiment show that this drug 
does not cause hepatic injury. It also does not cause cardiac injury, as shown by the CK 
activity assay. 
This study has demonstrated that SiPcGlu is an effective photosensitizer in treating 
HT29 cell lines and the preliminary animal study also shows that it is potent in inhibiting 
tumor growth in nude mice. However, its biodistribution problem highlights the need for 
further development of tumor-specific photosensitizer targeting for more effective PDT and 
new applications for photosensitizers. 
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5.2 Future Perspectives 
In the future work regarding the study of SiPcGlu-PDT, more in-depth in vitro and 
in vivo studies should be done to comprehensively evaluate its potential to reach clinical 
application. 
5.2.1 In vitro study 
5.2.1.1 Lysosomal pathway to cell death 
The accumulation of SiPcGlu in lysosomes may trigger a different cell death 
pathway. Some photosensitizers localize in lysosome and upon illumination they can cause 
cell death via two different routes, (1) via the release of lysosomal protease cathepsins in 
cytosol to trigger cytotoxicity or (2) via relocalization of the photosensitizer after 
illumination to other non-lysosomal targets (Moor, 2000). ATX-SlO(Na) was found to be 
localized in mitochondria and lysosomes. Pharmacological inhibitions of lysosomal 
protease cathepsins, such as cathepsin B and D, could protect cells from apoptosis (Ichinose 
et al., 2006). In the future, further investigation on the role of lysosome in triggering cell 
death may be addressed. 
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5.2.2 In vivo studies 
5.2.2.1 Pharmacokinetic studies 
In this study, the laser irradiation was done at 24 h after SiPcGlu injection. However, 
in order to have a better understanding on the pharmacokinetics of this compound, the ratio 
of SiPcGlu in tumor to different organs, especially skin, at different time intervals could 
also be evaluated for best tumor response. Bourre et al. (2003) reported that 2,3-dihydro-
5,15-di(3,5-dihydroxyphenyl)porphyrin (SIMOl) exhibited the highest retention in tumor 
between 6 to 12 h post injection and the optimal PDT response occurred during this time 
interval. Lassalle et al. (2009) also reported that after administration of liposomal 
formulations of meta-tetra(hydroxyphenyl)chlorine (mTHPC) to the EMT6 mouse 
mammary carcinoma xenografted nude mice, the highest tumor to muscle ratios were 
observed at 6 and 15 h post injection, and the best tumor response was also obtained during 
this interval. These studies indicates that the higher the tumor/tissue ratio, the better the 
therapeutic outcome and less cytotoxic effects to healthy tissue. In addition the clearance 
rate should also be investigated to study whether SiPcGlu can be cleared from the body 
rapidly. 
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5.2.2.2 Eradication of HT29 tumor by repeated dose of SiPcGlu 
Efficacy of PDT is limited by penetration of light into tissue (5-8 mm), so PDT can 
only be used for small lesions. Since PDT is a minimally invasive treatment and does not 
appear to succumb to multi-drug resistance and has no known cumulative dose ceiling as 
radiation and chemotherapy do, thus patients can be treated repeatedly as needed. Clinically, 
for the dosage and administration of photofrin®, a repeated light illumination can be applied 
50-70 h after the first illumination (information from the website of Photofrin®, 
http://www.photofrin.com/patient prescribing information.php?lang= 1 \ A repeated dose 
of topical methyl aminolevulinate-PDT has also been given to patients with nodular basal 
cell carcinoma in a previous clinical trial. The treatment was effective and exhibited a 
favorable cosmetic outcome (Rhodes et al., 2007). 
In this study only a single dose of treatment was applied to the nude mice, which 
may not be enough for complete eradication of the tumor, therefore a repeated dose of 
SiPcGlu-PDT may be applied to investigate whether complete eradication can be achieved. 
The evaluation for possible repeated-dose toxicity should also be accompanied. 
5.2.2.3 SiPcGlu-PDT-induced anti-tumor immunity 
Apoptosis or necrosis occurred after receiving PDT can provoke acute inflammatory 
response at the site of damage. A lot of evidence shows that the outcome of PDT is greatly 
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dependent on the contribution of host response. Inflammatory cytokines and chemokines 
can also be attributed to the immune response after PDT. T-lymphocytes can also be 
activated to become effector T cells, attracted by chemokines, migrate to the tumor and kil l 
the tumor cells. Therefore, further study on the anti-tumor immunity such as studying the 
level of the inflammatory cytokines or chemokines in the plasma of PDT-treated BALB/c 
mice may provide insight on how SiPcGlu-PDT works with the immune system to trigger 
anti-tumor effect. 
5.2.2.4 Enhancement of tumor selectivity by conjugating with 
biomolecules 
Although the glucose moiety of SiPcGlu can enhance the drug's water solubility, it 
failed to achieve tumor targeting. There is a need to formulate this compound by 
conjugating with other biomolecules, antibodies, tumor-specific antigens or encapsulating it 
with molecular carriers like nanoparticles or liposomes to enhance uptake specifically into 
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